{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:55:22Z","timestamp":1791590122906,"version":"4.3.4"},"reference-count":289,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10562-7","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:51:44Z","timestamp":1758988304000},"page":"1443-1480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Diabetic cardiomyopathy: Mechanistic insights on molecular pathways and emerging therapeutic approaches"],"prefix":"10.1007","volume":"30","author":[{"given":"Rupinder","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhdeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragati","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shareen","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvik","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"10562_CR1","doi-asserted-by":"publisher","first-page":"414750","DOI":"10.3389\/FPHYS.2018.01514\/XML","volume":"9","author":"G Borghetti","year":"2018","unstructured":"Borghetti G, Von Lewinski D, Eaton DM et al (2018) Diabetic cardiomyopathy: current and future therapies. Beyond glycemic control Front Physiol 9:414750. https:\/\/doi.org\/10.3389\/FPHYS.2018.01514\/XML","journal-title":"Beyond glycemic control Front Physiol"},{"key":"10562_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.JSBMB.2019.105575","volume":"198","author":"Q Gan","year":"2020","unstructured":"Gan Q, Wang J, Hu J et al (2020) The role of diosgenin in diabetes and diabetic complications. J Steroid Biochem Mol Biol 198:105575. https:\/\/doi.org\/10.1016\/J.JSBMB.2019.105575","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10562_CR3","doi-asserted-by":"publisher","unstructured":"Dutt J, Sapra A, Sheth-Dutt P et al (2020) Stevens-Johnson syndrome: a perplexing diagnosis. https:\/\/doi.org\/10.7759\/cureus.7374","DOI":"10.7759\/cureus.7374"},{"key":"10562_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/J.PHARMTHERA.2014.01.003","volume":"142","author":"K Huynh","year":"2014","unstructured":"Huynh K, Bernardo BC, McMullen JR, Ritchie RH (2014) Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 142:375\u2013415. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2014.01.003","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10562_CR5","first-page":"132","volume":"5","author":"K Parveen","year":"2016","unstructured":"Parveen K, Siddiqui WA, Kausar A et al (2016) Diabetic nephropathy-a major macrovascular complication. International J Pharm Res Allied Sci 5(4):132\u2013158. Available online www.ijpras.com.\u00a0Accessed 1 Jan 2016","journal-title":"International J Pharm Res Allied Sci"},{"key":"10562_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/J.MPMED.2018.11.011","volume":"47","author":"S Vella","year":"2019","unstructured":"Vella S, Petrie JR (2019) Macrovascular disease: pathogenesis and risk assessment. Medicine 47:65\u201371. https:\/\/doi.org\/10.1016\/J.MPMED.2018.11.011","journal-title":"Medicine"},{"key":"10562_CR7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/CVR\/CVAC152","volume":"119","author":"F Lezoualc\u2019h","year":"2023","unstructured":"Lezoualc\u2019h F, Badimon L, Baker H et al (2023) Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality. Cardiovasc Res 119:1130\u20131145. https:\/\/doi.org\/10.1093\/CVR\/CVAC152","journal-title":"Cardiovasc Res"},{"key":"10562_CR8","doi-asserted-by":"publisher","first-page":"1032268","DOI":"10.3389\/FENDO.2022.1032268\/XML","volume":"13","author":"X Zhao","year":"2022","unstructured":"Zhao X, Liu S, Wang X et al (2022) Diabetic cardiomyopathy: clinical phenotype and practice. Front Endocrinol (Lausanne) 13:1032268. https:\/\/doi.org\/10.3389\/FENDO.2022.1032268\/XML","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10562_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-017-0506-X","volume":"16","author":"A Lorenzo-Almor\u00f3s","year":"2017","unstructured":"Lorenzo-Almor\u00f3s A, Tu\u00f1\u00f3n J, Orejas M et al (2017) Diagnostic approaches for diabetic cardiomyopathy. Cardiovascular Diabetology 16:1\u201314. https:\/\/doi.org\/10.1186\/S12933-017-0506-X","journal-title":"Cardiovascular Diabetology"},{"key":"10562_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20133264","volume":"20","author":"I Evangelista","year":"2019","unstructured":"Evangelista I, Nuti R, Picchioni T et al (2019) Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy. Int J Mol Sci 20:3264. https:\/\/doi.org\/10.3390\/IJMS20133264","journal-title":"Int J Mol Sci"},{"key":"10562_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8214541","volume":"2017","author":"J Tian","year":"2017","unstructured":"Tian J, Zhao Y, Liu Y (2017) Roles and mechanisms of herbal medicine for diabetic cardiomyopathy: current status and perspective. Oxid Med Cell Longev 2017:8214541. https:\/\/doi.org\/10.1155\/2017\/8214541","journal-title":"Oxid Med Cell Longev"},{"key":"10562_CR12","doi-asserted-by":"publisher","unstructured":"Jia G, DeMarco VG, Sowers JR (2015) Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nature Reviews Endocrinology 2015 12:3 12:144\u2013153. https:\/\/doi.org\/10.1038\/nrendo.2015.216","DOI":"10.1038\/nrendo.2015.216"},{"key":"10562_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12916-024-03401-3\/TABLES\/3","volume":"22","author":"I Swiatkiewicz","year":"2024","unstructured":"Swiatkiewicz I, Patel NT, Villarreal-Gonzalez MA, Taub PR (2024) Prevalence of diabetic cardiomyopathy in patients with type 2 diabetes in a large academic medical center. BMC Med 22:1\u201315. https:\/\/doi.org\/10.1186\/S12916-024-03401-3\/TABLES\/3","journal-title":"BMC Med"},{"key":"10562_CR14","doi-asserted-by":"publisher","unstructured":"Jia G, Hill MA, Sowers JR (2018) Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res 122:624\u2013638. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311586\/ASSET\/9A28EDB1-1C29-484C-AB74-3C155D321551\/ASSETS\/IMAGES\/LARGE\/624FIG02.JPG","DOI":"10.1161\/CIRCRESAHA.117.311586\/ASSET\/9A28EDB1-1C29-484C-AB74-3C155D321551\/ASSETS\/IMAGES\/LARGE\/624FIG02.JPG"},{"key":"10562_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12916-017-0901-X","volume":"15","author":"H Kolb","year":"2017","unstructured":"Kolb H, Martin S (2017) Environmental\/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med 15:1\u201311. https:\/\/doi.org\/10.1186\/S12916-017-0901-X","journal-title":"BMC Med"},{"key":"10562_CR16","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1007\/S00125-012-2681-3\/TABLES\/3","volume":"55","author":"M Lind","year":"2012","unstructured":"Lind M, Olsson M, Rosengren A et al (2012) The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia 55:2946\u20132953. https:\/\/doi.org\/10.1007\/S00125-012-2681-3\/TABLES\/3","journal-title":"Diabetologia"},{"issue":"24","key":"10562_CR17","doi-asserted-by":"publisher","first-page":"e013871","DOI":"10.1161\/JAHA.119.013871\/SUPPL_FILE\/JAH34666-SUP-0001-SUPINFO.PDF","volume":"8","author":"J Edqvist","year":"2019","unstructured":"Edqvist J, Rawshani A, Adiels M et al (2019) Contrasting associations of body mass index and hemoglobin a1c on the excess risk of acute myocardial infarction and heart failure in type 2 diabetes mellitus. J Am Heart Assoc 8(24):e013871. https:\/\/doi.org\/10.1161\/JAHA.119.013871\/SUPPL_FILE\/JAH34666-SUP-0001-SUPINFO.PDF","journal-title":"J Am Heart Assoc"},{"key":"10562_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/J.JACC.2013.10.063","volume":"63","author":"SH Wan","year":"2013","unstructured":"Wan SH, Vogel MW, Chen HH (2013) Preclinical diastolic dysfunction. J Am Coll Cardiol 63:407. https:\/\/doi.org\/10.1016\/J.JACC.2013.10.063","journal-title":"J Am Coll Cardiol"},{"key":"10562_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIOX10030414","volume":"10","author":"A Menzel","year":"2021","unstructured":"Menzel A, Samouda H, Dohet F et al (2021) Common and novel markers for measuring inflammation and oxidative stress ex vivo in research and clinical practice\u2014which to use regarding disease outcomes? Antioxidants 10:414. https:\/\/doi.org\/10.3390\/ANTIOX10030414","journal-title":"Antioxidants"},{"key":"10562_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/S40119-022-00260-Y","volume":"11","author":"BY Sayin","year":"2022","unstructured":"Sayin BY, Oto A (2022) Left ventricular hypertrophy: etiology-based therapeutic options. Cardiol Ther 11:203. https:\/\/doi.org\/10.1007\/S40119-022-00260-Y","journal-title":"Cardiol Ther"},{"key":"10562_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS17122136","volume":"17","author":"ME H\u00f6lscher","year":"2016","unstructured":"H\u00f6lscher ME, Bode C, Bugger H (2016) Diabetic cardiomyopathy: does the type of diabetes matter? Int J Mol Sci 17:2136. https:\/\/doi.org\/10.3390\/IJMS17122136","journal-title":"Int J Mol Sci"},{"key":"10562_CR22","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.3390\/BIOMEDICINES10092274","volume":"10","author":"T Salvatore","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A et al (2022) Coronary microvascular dysfunction in diabetes mellitus: pathogenetic mechanisms and potential therapeutic options. Biomedicines 10:2274. https:\/\/doi.org\/10.3390\/BIOMEDICINES10092274","journal-title":"Biomedicines"},{"key":"10562_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/DIAGNOSTICS15010113","volume":"15","author":"A Mouzarou","year":"2025","unstructured":"Mouzarou A, Hadjigeorgiou N, Melanarkiti D, Plakomyti TE (2025) The role of NT-proBNP levels in the diagnosis of hypertensive heart disease. Diagnostics 15:113. https:\/\/doi.org\/10.3390\/DIAGNOSTICS15010113","journal-title":"Diagnostics"},{"key":"10562_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/JPM13030474","volume":"13","author":"ML Ruiz-Franco","year":"2023","unstructured":"Ruiz-Franco ML, Guevara-S\u00e1nchez E, Amaya-Pascasio L et al (2023) N-terminal pro-brain natriuretic peptide levels are associated with post-stroke in-hospital complications. J Pers Med 13:474. https:\/\/doi.org\/10.3390\/JPM13030474","journal-title":"J Pers Med"},{"key":"10562_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/S10554-008-9414-1\/METRICS","volume":"25","author":"GC Nesbitt","year":"2009","unstructured":"Nesbitt GC, Mankad S, Oh JK (2009) Strain imaging in echocardiography: methods and clinical applications. Int J Cardiovasc Imaging 25:9\u201322. https:\/\/doi.org\/10.1007\/S10554-008-9414-1\/METRICS","journal-title":"Int J Cardiovasc Imaging"},{"key":"10562_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/HRT.2005.071290","volume":"93","author":"H Mahrholdt","year":"2007","unstructured":"Mahrholdt H, Klem I, Sechtem U (2007) Cardiovascular MRI for detection of myocardial viability and ischaemia. Heart 93:122. https:\/\/doi.org\/10.1136\/HRT.2005.071290","journal-title":"Heart"},{"key":"10562_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3390\/JCM11030578","volume":"11","author":"G Casas","year":"2022","unstructured":"Casas G, Rodr\u00edguez-Palomares JF (2022) Multimodality cardiac imaging in cardiomyopathies: from diagnosis to prognosis. J Clin Med 11:578. https:\/\/doi.org\/10.3390\/JCM11030578","journal-title":"J Clin Med"},{"key":"10562_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-023-01816-5","volume":"22","author":"K Huang","year":"2023","unstructured":"Huang K, Luo X, Liao B et al (2023) Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovasc Diabetol 22:1\u201323. https:\/\/doi.org\/10.1186\/S12933-023-01816-5","journal-title":"Cardiovasc Diabetol"},{"key":"10562_CR29","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1042\/BCJ20160503C","volume":"473","author":"P Newsholme","year":"2016","unstructured":"Newsholme P, Cruzat VF, Keane KN (2016) Molecular mechanisms of ROS production and oxidative stress in diabetes. Biochem J 473:4527\u20134550. https:\/\/doi.org\/10.1042\/BCJ20160503C","journal-title":"Biochem J"},{"key":"10562_CR30","doi-asserted-by":"publisher","first-page":"907757","DOI":"10.3389\/FENDO.2022.907757\/XML","volume":"13","author":"ML Peng","year":"2022","unstructured":"Peng ML, Fu Y, Wu CW et al (2022) Signaling pathways related to oxidative stress in diabetic cardiomyopathy. Front Endocrinol (Lausanne) 13:907757. https:\/\/doi.org\/10.3389\/FENDO.2022.907757\/XML","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10562_CR31","doi-asserted-by":"publisher","unstructured":"Jubaidi FF, Zainalabidin S, Taib IS et al (2021) The potential role of flavonoids in ameliorating diabetic cardiomyopathy via alleviation of cardiac oxidative stress, inflammation and apoptosis. Int J Mol Sci 22:5094. https:\/\/doi.org\/10.3390\/IJMS22105094","DOI":"10.3390\/IJMS22105094"},{"key":"10562_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.23876\/J.KRCP.22.069","volume":"41","author":"V Ravarotto","year":"2022","unstructured":"Ravarotto V, Bertoldi G, Stefanelli LF et al (2022) Pathomechanism of oxidative stress in cardiovascular-renal remodeling and therapeutic strategies. Kidney Res Clin Pract 41:533. https:\/\/doi.org\/10.23876\/J.KRCP.22.069","journal-title":"Kidney Res Clin Pract"},{"key":"10562_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/ANTIOX13040455","volume":"13","author":"N Wang","year":"2024","unstructured":"Wang N, Zhang C (2024) Oxidative stress: a culprit in the progression of diabetic kidney disease. Antioxidants 13:455. https:\/\/doi.org\/10.3390\/ANTIOX13040455","journal-title":"Antioxidants"},{"key":"10562_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/S10741-013-9377-8\/METRICS","volume":"19","author":"M Isfort","year":"2014","unstructured":"Isfort M, Stevens SCW, Schaffer S et al (2014) Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev 19:35\u201348. https:\/\/doi.org\/10.1007\/S10741-013-9377-8\/METRICS","journal-title":"Heart Fail Rev"},{"key":"10562_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-023-02078-X\/FIGURES\/8","volume":"23","author":"S Zhang","year":"2024","unstructured":"Zhang S, Tian W, Duan X et al (2024) Melatonin attenuates diabetic cardiomyopathy by increasing autophagy of cardiomyocytes via regulation of VEGF-B\/GRP78\/PERK signaling pathway. Cardiovasc Diabetol 23:1\u201318. https:\/\/doi.org\/10.1186\/S12933-023-02078-X\/FIGURES\/8","journal-title":"Cardiovasc Diabetol"},{"key":"10562_CR36","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jchf.2017.07.013","volume":"5","author":"A Sharma","year":"2017","unstructured":"Sharma A, Stevens SR, Lucas J et al (2017) Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study. JACC Heart Fail 5:724\u2013734. https:\/\/doi.org\/10.1016\/j.jchf.2017.07.013","journal-title":"JACC Heart Fail"},{"key":"10562_CR37","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1002\/EHF2.14120","volume":"9","author":"V Bracun","year":"2022","unstructured":"Bracun V, van Essen B, Voors AA (2022) Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence. ESC Heart Fail 9:4167. https:\/\/doi.org\/10.1002\/EHF2.14120","journal-title":"ESC Heart Fail"},{"key":"10562_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4103\/JCN.JCN_77_19","volume":"9","author":"A Saleeh","year":"2020","unstructured":"Saleeh A, Fouad M, Mosbah B-E, Khashana A (2020) Activin A is a novel biomarker in early screening of neonatal sepsis. J Clin Neonatol 9:32. https:\/\/doi.org\/10.4103\/JCN.JCN_77_19","journal-title":"J Clin Neonatol"},{"key":"10562_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8773423","volume":"2021","author":"N Yang","year":"2021","unstructured":"Yang N, Wu J, Zhang T et al (2021) Clinical evaluation of FOXO1 as a tumor suppressor in prostate cancer. Comput Math Methods Med 2021:8773423. https:\/\/doi.org\/10.1155\/2021\/8773423","journal-title":"Comput Math Methods Med"},{"key":"10562_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/HIS.14898","volume":"83","author":"CD Rutland","year":"2023","unstructured":"Rutland CD, Gedallovich J, Wang A (2023) Diagnostic utility of FOXO1 immunohistochemistry for rhabdomyosarcoma classification. Histopathology 83:49\u201356. https:\/\/doi.org\/10.1111\/HIS.14898","journal-title":"Histopathology"},{"key":"10562_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12916-023-02887-7\/FIGURES\/9","volume":"21","author":"X Zhang","year":"2023","unstructured":"Zhang X, Duan Y, Zhang X et al (2023) Adipsin alleviates cardiac microvascular injury in diabetic cardiomyopathy through Csk-dependent signaling mechanism. BMC Med 21:1\u201322. https:\/\/doi.org\/10.1186\/S12916-023-02887-7\/FIGURES\/9","journal-title":"BMC Med"},{"key":"10562_CR42","doi-asserted-by":"publisher","unstructured":"Parim B, Sathibabu Uddandrao VV, Saravanan G (2018) Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy. Heart Failure Reviews 2:24:279\u2013299. https:\/\/doi.org\/10.1007\/S10741-018-9749-1","DOI":"10.1007\/S10741-018-9749-1"},{"key":"10562_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2024.107057","volume":"200","author":"Z Chen","year":"2024","unstructured":"Chen Z, Li S, Liu M et al (2024) Nicorandil alleviates cardiac microvascular ferroptosis in diabetic cardiomyopathy: role of the mitochondria-localized AMPK-Parkin-ACSL4 signaling pathway. Pharmacol Res 200:107057. https:\/\/doi.org\/10.1016\/J.PHRS.2024.107057","journal-title":"Pharmacol Res"},{"key":"10562_CR44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/J.2040-4603.2017.TB00752.X","volume":"7","author":"X Hu","year":"2017","unstructured":"Hu X, Bai T, Xu Z et al (2017) Pathophysiological fundamentals of diabetic cardiomyopathy. Compr Physiol 7:693\u2013711. https:\/\/doi.org\/10.1002\/J.2040-4603.2017.TB00752.X","journal-title":"Compr Physiol"},{"key":"10562_CR45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/J.PCAD.2019.03.003","volume":"62","author":"G Murtaza","year":"2019","unstructured":"Murtaza G, Virk H UH, Khalid M et al (2019) Diabetic cardiomyopathy - a comprehensive updated review. Prog Cardiovasc Dis 62:315\u2013326. https:\/\/doi.org\/10.1016\/J.PCAD.2019.03.003","journal-title":"Prog Cardiovasc Dis"},{"key":"10562_CR46","first-page":"104","volume":"62","author":"S Diana","year":"2019","unstructured":"Diana S, Svetlana G, Valeriu I (2019) Diabetic cardiomyopathy and diastolic heart failure. Bul Acad Stiinte Repub Mold Stiinte Med 62:104\u2013110","journal-title":"Bul Acad Stiinte Repub Mold Stiinte Med"},{"key":"10562_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20112833","volume":"20","author":"M Zamora","year":"2019","unstructured":"Zamora M, Villena JA (2019) Contribution of impaired insulin signaling to the pathogenesis of diabetic cardiomyopathy. Int J Mol Sci 20:2833. https:\/\/doi.org\/10.3390\/IJMS20112833","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10562_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS26094209","volume":"26","author":"T Ponce-Lopez","year":"2025","unstructured":"Ponce-Lopez T (2025) Peripheral inflammation and insulin resistance: their impact on blood\u2013brain barrier integrity and glia activation in Alzheimer\u2019s disease. Int J Mol Sci 26(9):4209. https:\/\/doi.org\/10.3390\/IJMS26094209","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10562_CR49","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/S00125-021-05415-5","volume":"64","author":"TM Batista","year":"2021","unstructured":"Batista TM, Haider N, Kahn CR (2021) Defining the underlying defect in insulin action in type 2 diabetes. Diabetologia 64(5):994\u20131006. https:\/\/doi.org\/10.1007\/S00125-021-05415-5","journal-title":"Diabetologia"},{"key":"10562_CR50","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.2174\/0929867322666150812145035","volume":"22","author":"D Lauro","year":"2015","unstructured":"Lauro D, Pastore D, Capuani B et al (2015) Role of serum and glucocorticoid-inducible kinase (SGK)-1 in senescence: a novel molecular target against age-related diseases. Curr Med Chem 22:3765\u20133788. https:\/\/doi.org\/10.2174\/0929867322666150812145035","journal-title":"Curr Med Chem"},{"key":"10562_CR51","doi-asserted-by":"publisher","unstructured":"Spoladore R, Pinto G, Daus F et al (2023) Metabolic approaches for the treatment of dilated cardiomyopathy. J Cardiovasc Dev Dis 10:287. https:\/\/doi.org\/10.3390\/JCDD10070287","DOI":"10.3390\/JCDD10070287"},{"key":"10562_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/J.REDOX.2021.101964","volume":"42","author":"C Lennicke","year":"2021","unstructured":"Lennicke C, Cochem\u00e9 HM (2021) Redox regulation of the insulin signalling pathway. Redox Biol 42:101964. https:\/\/doi.org\/10.1016\/J.REDOX.2021.101964","journal-title":"Redox Biol"},{"key":"10562_CR53","doi-asserted-by":"publisher","unstructured":"Kwon H, Pessin JE (2020) Insulin-mediated PI3K and AKT signaling. The liver: biology and pathobiology 485\u2013495.https:\/\/doi.org\/10.1002\/9781119436812.CH39;CTYPE:STRING:BOOK","DOI":"10.1002\/9781119436812.CH39;CTYPE:STRING:BOOK"},{"key":"10562_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/J.DIABRES.2017.10.004","volume":"156","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Liu H, Liu J (2019) Akt activation: a potential strategy to ameliorate insulin resistance. Diabetes Res Clin Pract 156:107092. https:\/\/doi.org\/10.1016\/J.DIABRES.2017.10.004","journal-title":"Diabetes Res Clin Pract"},{"key":"10562_CR55","doi-asserted-by":"publisher","unstructured":"Tran N, Garcia T, Aniqa M, et al (2022) Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: in physiology and in disease states. Am J Biomed Sci Res 15:153. https:\/\/doi.org\/10.34297\/ajbsr.2022.15.002087","DOI":"10.34297\/ajbsr.2022.15.002087"},{"key":"10562_CR56","doi-asserted-by":"publisher","first-page":"516191","DOI":"10.3389\/FCVM.2020.00034\/XML","volume":"7","author":"W Parichatikanond","year":"2020","unstructured":"Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H (2020) Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on tgf-\u03b2 Signaling. Front Cardiovasc Med 7:516191. https:\/\/doi.org\/10.3389\/FCVM.2020.00034\/XML","journal-title":"Front Cardiovasc Med"},{"key":"10562_CR57","doi-asserted-by":"publisher","unstructured":"Turner NA, Blythe NM (2019) Cardiac Fibroblast p38 MAPK: a critical regulator of myocardial remodeling. J Cardiovasc Dev Dis 6:27. https:\/\/doi.org\/10.3390\/JCDD6030027","DOI":"10.3390\/JCDD6030027"},{"key":"10562_CR58","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9583268","volume":"2016","author":"P Xia","year":"2016","unstructured":"Xia P, Liu Y, Cheng Z (2016) Signaling pathways in cardiac myocyte apoptosis. BioMed Res Int 2016:9583268. https:\/\/doi.org\/10.1155\/2016\/9583268","journal-title":"BioMed Res Int"},{"key":"10562_CR59","doi-asserted-by":"publisher","DOI":"10.1530\/JME-23-0066","volume":"71","author":"G Jia","year":"2023","unstructured":"Jia G, Hill MA, Sowers JR (2023) Vascular endothelial mineralocorticoid receptors and epithelial sodium channels in metabolic syndrome and related cardiovascular disease. J Mol Endocrinol 71:e230066. https:\/\/doi.org\/10.1530\/JME-23-0066","journal-title":"J Mol Endocrinol"},{"key":"10562_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/S00125-017-4390-4","volume":"61","author":"G Jia","year":"2017","unstructured":"Jia G, Whaley-Connell A, Sowers JR (2017) Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 61:21. https:\/\/doi.org\/10.1007\/S00125-017-4390-4","journal-title":"Diabetologia"},{"key":"10562_CR61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/A-2435-8264\/ID\/RHMR-2024-06-0256-0015\/BIB","volume":"57","author":"S Dwivedi","year":"2024","unstructured":"Dwivedi S, Sikarwar MS (2024) Diabetic nephropathy: pathogenesis, mechanisms, and therapeutic strategies. Horm Metab Res 57:7\u201317. https:\/\/doi.org\/10.1055\/A-2435-8264\/ID\/RHMR-2024-06-0256-0015\/BIB","journal-title":"Horm Metab Res"},{"key":"10562_CR62","doi-asserted-by":"publisher","first-page":"619426","DOI":"10.3389\/FPHAR.2020.619426\/BIBTEX","volume":"11","author":"XS Liu","year":"2021","unstructured":"Liu XS, Zeng J, Yang YX et al (2021) DRD4 mitigates myocardial ischemia\/reperfusion injury in association with PI3K\/AKT mediated glucose metabolism. Front Pharmacol 11:619426. https:\/\/doi.org\/10.3389\/FPHAR.2020.619426\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"10562_CR63","doi-asserted-by":"publisher","unstructured":"Alaimo A, Pallafacchina G, Zanin S et al (2025) Calcium signaling dynamics in vascular cells and their dysregulation in vascular disease. Biomolecules 15:892. https:\/\/doi.org\/10.3390\/BIOM15060892","DOI":"10.3390\/BIOM15060892"},{"key":"10562_CR64","doi-asserted-by":"publisher","first-page":"792798","DOI":"10.3389\/FPHAR.2022.792798\/XML","volume":"13","author":"G Numata","year":"2022","unstructured":"Numata G, Takimoto E (2022) Cyclic GMP and PKG signaling in heart failure. Front Pharmacol 13:792798. https:\/\/doi.org\/10.3389\/FPHAR.2022.792798\/XML","journal-title":"Front Pharmacol"},{"key":"10562_CR65","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/13543784.2023.2290064","volume":"32","author":"A Ajay","year":"2023","unstructured":"Ajay A, Rasoul D, Abdullah A et al (2023) Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure. Expert Opin Investig Drugs 32:1157\u20131170. https:\/\/doi.org\/10.1080\/13543784.2023.2290064","journal-title":"Expert Opin Investig Drugs"},{"key":"10562_CR66","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR (2018) Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res 122:624. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311586","journal-title":"Circ Res"},{"key":"10562_CR67","doi-asserted-by":"publisher","first-page":"C166","DOI":"10.1152\/AJPCELL.00021.2020\/ASSET\/IMAGES\/LARGE\/ZH00072087460002.JPEG","volume":"319","author":"E Tracy","year":"2020","unstructured":"Tracy E, Rowe G, LeBlanc AJ (2020) Cardiac tissue remodeling in healthy aging: the road to pathology. Am J Physiol Cell Physiol 319:C166\u2013C182. https:\/\/doi.org\/10.1152\/AJPCELL.00021.2020\/ASSET\/IMAGES\/LARGE\/ZH00072087460002.JPEG","journal-title":"Am J Physiol Cell Physiol"},{"key":"10562_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/NU11081748","volume":"11","author":"A Bettiga","year":"2019","unstructured":"Bettiga A, Fiorio F, Di Marco F et al (2019) The modern Western diet rich in advanced glycation end-products (AGEs): an overview of its impact on obesity and early progression of renal pathology. Nutrients 11:1748. https:\/\/doi.org\/10.3390\/NU11081748","journal-title":"Nutrients"},{"key":"10562_CR69","doi-asserted-by":"publisher","first-page":"483214","DOI":"10.3389\/FPHAR.2019.01420\/XML","volume":"10","author":"R Coppini","year":"2019","unstructured":"Coppini R, Santini L, Palandri C et al (2019) Pharmacological inhibition of serine proteases to reduce cardiac inflammation and fibrosis in atrial fibrillation. Front Pharmacol 10:483214. https:\/\/doi.org\/10.3389\/FPHAR.2019.01420\/XML","journal-title":"Front Pharmacol"},{"key":"10562_CR70","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1152\/AJPCELL.00331.2011\/ASSET\/IMAGES\/LARGE\/ZH00011268400005.JPEG","volume":"302","author":"RM Maalouf","year":"2012","unstructured":"Maalouf RM, Eid AA, Gorin YC et al (2012) Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes. Am J Physiol Cell Physiol 302:597\u2013604. https:\/\/doi.org\/10.1152\/AJPCELL.00331.2011\/ASSET\/IMAGES\/LARGE\/ZH00011268400005.JPEG","journal-title":"Am J Physiol Cell Physiol"},{"key":"10562_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S12276-019-0355-7","volume":"51","author":"JN Peoples","year":"2019","unstructured":"Peoples JN, Saraf A, Ghazal N et al (2019) Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med 51:1\u201313. https:\/\/doi.org\/10.1038\/S12276-019-0355-7","journal-title":"Exp Mol Med"},{"key":"10562_CR72","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/S00125-014-3171-6\/FIGURES\/1","volume":"57","author":"H Bugger","year":"2014","unstructured":"Bugger H, Abel ED (2014) Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57:660\u2013671. https:\/\/doi.org\/10.1007\/S00125-014-3171-6\/FIGURES\/1","journal-title":"Diabetologia"},{"key":"10562_CR73","doi-asserted-by":"publisher","first-page":"1162754","DOI":"10.3389\/FENDO.2023.1162754\/XML","volume":"14","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Wang Y, Yin R et al (2023) Central role of cardiac fibroblasts in myocardial fibrosis of diabetic cardiomyopathy. Front Endocrinol (Lausanne) 14:1162754. https:\/\/doi.org\/10.3389\/FENDO.2023.1162754\/XML","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10562_CR74","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/CELLS11030552","volume":"11","author":"YA Hajam","year":"2022","unstructured":"Hajam YA, Rani R, Ganie SY et al (2022) Oxidative stress in human pathology and aging: molecular mechanisms and perspectives. Cells 11:552. https:\/\/doi.org\/10.3390\/CELLS11030552","journal-title":"Cells"},{"key":"10562_CR75","first-page":"1090","volume":"19","author":"Z Rahimi","year":"2014","unstructured":"Rahimi Z, Moradi M, Nasri H (2014) A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. J Res Med Sci 19:1090","journal-title":"J Res Med Sci"},{"key":"10562_CR76","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3390\/BIOMEDICINES12081802","volume":"12","author":"SM Stanciu","year":"2024","unstructured":"Stanciu SM, Jinga M, Miricescu D et al (2024) Mtor dysregulation, insulin resistance, and hypertension. Biomedicines 12:1802. https:\/\/doi.org\/10.3390\/BIOMEDICINES12081802","journal-title":"Biomedicines"},{"key":"10562_CR77","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/J.CELL.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274. https:\/\/doi.org\/10.1016\/J.CELL.2012.03.017","journal-title":"Cell"},{"key":"10562_CR78","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/J.FREERADBIOMED.2022.12.097","volume":"195","author":"X Tan","year":"2023","unstructured":"Tan X, Chen Y, Zou S et al (2023) ALDH2 attenuates ischemia and reperfusion injury through regulation of mitochondrial fusion and fission by PI3K\/AKT\/mTOR pathway in diabetic cardiomyopathy. Free Radic Biol Med 195:219\u2013230. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2022.12.097","journal-title":"Free Radic Biol Med"},{"key":"10562_CR79","doi-asserted-by":"publisher","first-page":"1421838","DOI":"10.3389\/FENDO.2024.1421838\/XML","volume":"15","author":"M Tian","year":"2024","unstructured":"Tian M, Huang X, Li M et al (2024) Ferroptosis in diabetic cardiomyopathy: from its mechanisms to therapeutic strategies. Front Endocrinol (Lausanne) 15:1421838. https:\/\/doi.org\/10.3389\/FENDO.2024.1421838\/XML","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10562_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-022-01643-0","volume":"21","author":"H Wang","year":"2022","unstructured":"Wang H, Wang L, Hu F et al (2022) Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK\/mTOR signalling pathway. Cardiovasc Diabetol 21:1\u201315. https:\/\/doi.org\/10.1186\/S12933-022-01643-0","journal-title":"Cardiovasc Diabetol"},{"key":"10562_CR81","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1111\/BPH.15782","volume":"179","author":"CDCC van der Heijden","year":"2022","unstructured":"van der Heijden CDCC, Bode M, Riksen NP, Wenzel UO (2022) The role of the mineralocorticoid receptor in immune cells in cardiovascular disease. Br J Pharmacol 179:3135\u20133151. https:\/\/doi.org\/10.1111\/BPH.15782","journal-title":"Br J Pharmacol"},{"key":"10562_CR82","doi-asserted-by":"publisher","first-page":"659666","DOI":"10.3389\/FCELL.2021.659666\/XML","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu X, Shi GP, Guo J (2021) Innate immune cells in pressure overload-induced cardiac hypertrophy and remodeling. Front Cell Dev Biol 9:659666. https:\/\/doi.org\/10.3389\/FCELL.2021.659666\/XML","journal-title":"Front Cell Dev Biol"},{"key":"10562_CR83","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/j.1523-1755.2004.00513.x","volume":"65","author":"JFE Mann","year":"2004","unstructured":"Mann JFE, Lonn EM, Yi Q et al (2004) Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 65:1375\u20131380. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00513.x","journal-title":"Kidney Int"},{"key":"10562_CR84","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.2337\/DIACARE.25.11.1919","volume":"25","author":"E Lonn","year":"2002","unstructured":"Lonn E, Yusuf S, Hoogwerf B et al (2002) Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25:1919\u20131927. https:\/\/doi.org\/10.2337\/DIACARE.25.11.1919","journal-title":"Diabetes Care"},{"key":"10562_CR85","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.jvca.2010.04.022","volume":"25","author":"G Wang","year":"2011","unstructured":"Wang G, Bainbridge D, Martin J, Cheng D (2011) N-acetylcysteine in cardiac surgery: do the benefits outweigh the risks? A meta-analytic reappraisal. J Cardiothorac Vasc Anesth 25:268\u2013275. https:\/\/doi.org\/10.1053\/j.jvca.2010.04.022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10562_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/FCVM.2021.752939","author":"SA Khan","year":"2021","unstructured":"Khan SA, Campbell AM, Lu Y et al (2021) N-acetylcysteine for cardiac protection during coronary artery reperfusion: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/FCVM.2021.752939","journal-title":"Front Cardiovasc Med"},{"key":"10562_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/J.REDOX.2019.101100","volume":"21","author":"KY Goh","year":"2019","unstructured":"Goh KY, He L, Song J et al (2019) Mitoquinone ameliorates pressure overload-induced cardiac fibrosis and left ventricular dysfunction in mice. Redox Biol 21:101100. https:\/\/doi.org\/10.1016\/J.REDOX.2019.101100","journal-title":"Redox Biol"},{"key":"10562_CR88","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/ANTIOX11071232\/S1","volume":"11","author":"FV Souza-Neto","year":"2022","unstructured":"Souza-Neto FV, Islas F, Jim\u00e9nez-Gonz\u00e1lez S et al (2022) Mitochondrial oxidative stress promotes cardiac remodeling in myocardial infarction through the activation of endoplasmic reticulum stress. Antioxidants 11:1232. https:\/\/doi.org\/10.3390\/ANTIOX11071232\/S1","journal-title":"Antioxidants"},{"key":"10562_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2022.980783\/BIBTEX","volume":"13","author":"KO Murray","year":"2022","unstructured":"Murray KO, Berryman-Maciel M, Darvish S et al (2022) Mitochondrial-targeted antioxidant supplementation for improving age-related vascular dysfunction in humans: a study protocol. Front Physiol 13:980783. https:\/\/doi.org\/10.3389\/FPHYS.2022.980783\/BIBTEX","journal-title":"Front Physiol"},{"key":"10562_CR90","doi-asserted-by":"publisher","DOI":"10.7554\/ELIFE.55513","volume":"9","author":"YA Chiao","year":"2020","unstructured":"Chiao YA, Zhang H, Sweetwyne M et al (2020) Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. Elife 9:e55513. https:\/\/doi.org\/10.7554\/ELIFE.55513","journal-title":"Elife"},{"key":"10562_CR91","doi-asserted-by":"publisher","first-page":"858594","DOI":"10.3389\/FCVM.2022.858594\/FULL","volume":"9","author":"M Suo","year":"2022","unstructured":"Suo M, Qi Y, Liu L et al (2022) SS31 Alleviates pressure overload-induced heart failure caused by Sirt3-mediated mitochondrial fusion. Front Cardiovasc Med 9:858594. https:\/\/doi.org\/10.3389\/FCVM.2022.858594\/FULL","journal-title":"Front Cardiovasc Med"},{"key":"10562_CR92","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004389","author":"MA Daubert","year":"2017","unstructured":"Daubert MA, Yow E, Dunn G (2017) Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004389","journal-title":"Circ Heart Fail"},{"key":"10562_CR93","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cardfail.2020.02.001","volume":"26","author":"J Butler","year":"2020","unstructured":"Butler J, Khan MS, Anker SD et al (2020) Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial: effects of elamipretide in heart failure. J Card Fail 26:429\u2013437. https:\/\/doi.org\/10.1016\/j.cardfail.2020.02.001","journal-title":"J Card Fail"},{"key":"10562_CR94","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/CIRCULATIONAHA.114.011079","volume":"131","author":"QD Zhao","year":"2015","unstructured":"Zhao QD, Viswanadhapalli S, Williams P et al (2015) NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt\/mTOR and NF\u03baB signaling pathways. Circulation 131:643. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.011079","journal-title":"Circulation"},{"key":"10562_CR95","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/J.BIOPHA.2018.11.077","volume":"109","author":"S yuZeng","year":"2019","unstructured":"yuZeng S, Yang L, jiangYan Q et al (2019) Nox1\/4 dual inhibitor GKT137831 attenuates hypertensive cardiac remodelling associating with the inhibition of ADAM17-dependent proinflammatory cytokines-induced signalling pathways in the rats with abdominal artery constriction. Biomed Pharmacother 109:1907\u20131914. https:\/\/doi.org\/10.1016\/J.BIOPHA.2018.11.077","journal-title":"Biomed Pharmacother"},{"key":"10562_CR96","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/J.BIOPHA.2018.11.077","volume":"109","author":"S Zeng","year":"2019","unstructured":"Zeng S, Yang L, Yan Q et al (2019) Nox1\/4 dual inhibitor GKT137831 attenuates hypertensive cardiac remodelling associating with the inhibition of ADAM17-dependent proinflammatory cytokines-induced signalling pathways in the rats with abdominal artery constriction. Biomed Pharmacother 109:1907\u20131914. https:\/\/doi.org\/10.1016\/J.BIOPHA.2018.11.077","journal-title":"Biomed Pharmacother"},{"key":"10562_CR97","doi-asserted-by":"publisher","unstructured":"Heydarzadeh S, Ranjbar M, Karimi F et al (2021) Overview of host miRNA properties and their association with epigenetics, long non-coding RNAs, and Xeno-infectious factors. Cell & Bioscience 11:1\u201317. https:\/\/doi.org\/10.1186\/S13578-021-00552-1","DOI":"10.1186\/S13578-021-00552-1"},{"key":"10562_CR98","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/15384101.2022.2139126","volume":"22","author":"X Liu","year":"2023","unstructured":"Liu X, Liu Y, Tang L, Du C (2023) Inhibition of farnesyl pyrophosphate synthase alleviates cardiomyopathy in diabetic rat. Cell Cycle 22:666\u2013679. https:\/\/doi.org\/10.1080\/15384101.2022.2139126","journal-title":"Cell Cycle"},{"key":"10562_CR99","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.3390\/CELLS10113259","volume":"10","author":"RB Devereux","year":"2021","unstructured":"Devereux RB, Roman MJ, Paranicas M et al (2021) The contribution of cardiac fatty acid oxidation to diabetic cardiomyopathy severity. Cells 10:3259. https:\/\/doi.org\/10.3390\/CELLS10113259","journal-title":"Cells"},{"key":"10562_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-44942-7.00067-4","volume":"394\u2013404","author":"H G\u00f3mez","year":"2019","unstructured":"G\u00f3mez H, Mizock BA (2019) Hyperlactatemia and lactic acidosis. Critical care nephrology: third edition 394\u2013404:e3. https:\/\/doi.org\/10.1016\/B978-0-323-44942-7.00067-4","journal-title":"Critical care nephrology: third edition"},{"key":"10562_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/FMOLB.2020.00076\/XML","volume":"7","author":"B Ahmad","year":"2020","unstructured":"Ahmad B, Serpell CJ, Fong IL, Wong EH (2020) Molecular mechanisms of adipogenesis: the anti-adipogenic role of AMP-activated protein kinase. Front Mol Biosci 7:533745. https:\/\/doi.org\/10.3389\/FMOLB.2020.00076\/XML","journal-title":"Front Mol Biosci"},{"issue":"3","key":"10562_CR102","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1161\/01.ATV.0000155325.41507.E0","volume":"25","author":"C Rask-Madsen","year":"2005","unstructured":"Rask-Madsen C, King GL (2005) Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 25(3):487\u2013496. https:\/\/doi.org\/10.1161\/01.ATV.0000155325.41507.E0","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10562_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-1-1","volume":"1","author":"D Aronson","year":"2002","unstructured":"Aronson D, Rayfield EJ (2002) How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 1:1\u20131. https:\/\/doi.org\/10.1186\/1475-2840-1-1","journal-title":"Cardiovasc Diabetol"},{"key":"10562_CR104","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2337\/DIABETES.49.7.1239","volume":"49","author":"JY Park","year":"2000","unstructured":"Park JY, Takahara N, Gabriele A et al (2000) Induction of endothelin-1 expression by glucose an effect of protein kinase C activation. Diabetes 49:1239\u20131248. https:\/\/doi.org\/10.2337\/DIABETES.49.7.1239","journal-title":"Diabetes"},{"key":"10562_CR105","doi-asserted-by":"publisher","unstructured":"Dushpanova A, Agostini S, Ciofini E, et al (2016) Gene silencing of endothelial von Willebrand Factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. Sci Rep 6:1\u201312. https:\/\/doi.org\/10.1038\/srep30048","DOI":"10.1038\/srep30048"},{"issue":"4","key":"10562_CR106","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/CIRCRESAHA.118.313237","volume":"123","author":"X Pi","year":"2018","unstructured":"Pi X, Xie L, Patterson C (2018) Emerging roles of vascular endothelium in metabolic homeostasis. Circ Res 123(4):477\u2013494. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313237","journal-title":"Circ Res"},{"key":"10562_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/J.YMGMR.2024.101183","volume":"42","author":"PK Praveen","year":"2024","unstructured":"Praveen PK, Jyothi MN, Prashant A (2024) Mitochondrial DNA variants in the pathogenesis and metabolic alterations of diabetes mellitus. Mol Genet Metab Rep 42:101183. https:\/\/doi.org\/10.1016\/J.YMGMR.2024.101183","journal-title":"Mol Genet Metab Rep"},{"key":"10562_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/J.METABOL.2021.154910","volume":"125","author":"SS Jankauskas","year":"2021","unstructured":"Jankauskas SS, Kansakar U, Varzideh F et al (2021) Heart failure in diabetes. Metabolism 125:154910. https:\/\/doi.org\/10.1016\/J.METABOL.2021.154910","journal-title":"Metabolism"},{"key":"10562_CR109","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mam.2018.07.001","volume":"65","author":"NG Frangogiannis","year":"2019","unstructured":"Frangogiannis NG (2019) Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med 65:70\u201399. https:\/\/doi.org\/10.1016\/j.mam.2018.07.001","journal-title":"Mol Aspects Med"},{"key":"10562_CR110","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.addr.2019.05.011","volume":"146","author":"S Hinderer","year":"2019","unstructured":"Hinderer S, Schenke-Layland K (2019) Cardiac fibrosis \u2013 a short review of causes and therapeutic strategies. Adv Drug Deliv Rev 146:77\u201382. https:\/\/doi.org\/10.1016\/j.addr.2019.05.011","journal-title":"Adv Drug Deliv Rev"},{"key":"10562_CR111","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","volume":"118","author":"JG Travers","year":"2016","unstructured":"Travers JG, Kamal FA, Robbins J et al (2016) Cardiac fibrosis: the fibroblast awakens. Circ Res 118:1021\u20131040. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306565","journal-title":"Circ Res"},{"key":"10562_CR112","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCRESAHA.114.302533","volume":"114","author":"M Rienks","year":"2014","unstructured":"Rienks M, Papageorgiou AP, Frangogiannis NG, Heymans S (2014) Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res 114:872\u2013888. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.302533","journal-title":"Circ Res"},{"key":"10562_CR113","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/S00018-013-1349-6","volume":"71","author":"P Kong","year":"2014","unstructured":"Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71:549\u2013574. https:\/\/doi.org\/10.1007\/S00018-013-1349-6","journal-title":"Cell Mol Life Sci"},{"key":"10562_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2024.E41157","volume":"11","author":"X Wang","year":"2025","unstructured":"Wang X, Yu S, Xie L (2025) The role of the extracellular matrix in cardiac regeneration. Heliyon 11:e41157. https:\/\/doi.org\/10.1016\/J.HELIYON.2024.E41157","journal-title":"Heliyon"},{"key":"10562_CR115","doi-asserted-by":"publisher","unstructured":"Cabral-Pacheco GA, Garza-Veloz I, Rosa CCD La et al (2020) The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci 21:9739. https:\/\/doi.org\/10.3390\/IJMS21249739","DOI":"10.3390\/IJMS21249739"},{"key":"10562_CR116","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/CVR\/CVAD100","volume":"119","author":"L Da Dalt","year":"2023","unstructured":"Da Dalt L, Cabodevilla AG, Goldberg IJ, Norata GD (2023) Cardiac lipid metabolism, mitochondrial function, and heart failure. Cardiovasc Res 119:1905\u20131914. https:\/\/doi.org\/10.1093\/CVR\/CVAD100","journal-title":"Cardiovasc Res"},{"key":"10562_CR117","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez MS, Garc\u00eda A, Luzardo E, et al (2017) Energetic metabolism in cardiomyocytes: molecular basis of heart ischemia and arrhythmogenesis. Vessel Plus 1:130\u2013141. https:\/\/doi.org\/10.20517\/2574-1209.2017.34","DOI":"10.20517\/2574-1209.2017.34"},{"key":"10562_CR118","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.2174\/1381612822666160307145931","volume":"22","author":"W Hassan","year":"2016","unstructured":"Hassan W, Noreen H, Castro-Gomes V et al (2016) Association of oxidative stress with psychiatric disorders. Curr Pharm Des 22:2960\u20132974. https:\/\/doi.org\/10.2174\/1381612822666160307145931","journal-title":"Curr Pharm Des"},{"key":"10562_CR119","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1161\/CIRCULATIONAHA.115.018585","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D (2016) Dietary and policy priorities for cardiovascular disease, diabetes, and obesity. Circulation 133:187\u2013225. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018585","journal-title":"Circulation"},{"key":"10562_CR120","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/J.FREERADBIOMED.2020.02.025","volume":"152","author":"Z Chen","year":"2020","unstructured":"Chen Z, Tian R, She Z et al (2020) Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 152:116\u2013141. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2020.02.025","journal-title":"Free Radic Biol Med"},{"key":"10562_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2025.107615","volume":"212","author":"M Song","year":"2025","unstructured":"Song M, Bai Y, Song F (2025) High-fat diet and neuroinflammation: the role of mitochondria. Pharmacol Res 212:107615. https:\/\/doi.org\/10.1016\/J.PHRS.2025.107615","journal-title":"Pharmacol Res"},{"key":"10562_CR122","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3904\/KJIM.2016.208","volume":"32","author":"WS Lee","year":"2017","unstructured":"Lee WS, Kim J (2017) Diabetic cardiomyopathy: where we are and where we are going. Korean J Intern Med 32:404. https:\/\/doi.org\/10.3904\/KJIM.2016.208","journal-title":"Korean J Intern Med"},{"key":"10562_CR123","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.2337\/DC10-S089","volume":"33","author":"MM Funnell","year":"2010","unstructured":"Funnell MM, Brown TL, Childs BP et al (2010) National standards for diabetes self-management education. Diabetes Care 33:S89. https:\/\/doi.org\/10.2337\/DC10-S089","journal-title":"Diabetes Care"},{"issue":"1","key":"10562_CR124","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s43016-019-0013-1","volume":"1","author":"D Mozaffarian","year":"2020","unstructured":"Mozaffarian D (2020) Dietary and policy priorities to reduce the global crises of obesity and diabetes. Nat Food 1(1):38\u201350. https:\/\/doi.org\/10.1038\/s43016-019-0013-1","journal-title":"Nat Food"},{"key":"10562_CR125","unstructured":"Awuchi CG, Kate Echeta C (2020) Diabetes and the nutrition and diets for its prevention and treatment: a systematic review and dietetic perspective citation Chinaza Godswill Awuchi, Chinelo Kate Echeta, Victory Somtochukwu Igwe. Diabetes and the Nutrition and Diets for Its Prevention and Treatment: A Systematic Review and Dietetic Perspective. Health Sciences Research 6:5\u201319"},{"key":"10562_CR126","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5152\/EURASIANJMED.2018.18298","volume":"51","author":"MN Akcay","year":"2019","unstructured":"Akcay MN, Karadeniz E, Ahiskalioglu A (2019) Bariatric\/metabolic surgery in type 1 and type 2 diabetes mellitus. Eurasian J Med 51:85. https:\/\/doi.org\/10.5152\/EURASIANJMED.2018.18298","journal-title":"Eurasian J Med"},{"key":"10562_CR127","doi-asserted-by":"publisher","unstructured":"Raveendran AV, Chacko EC, Pappachan JM (2018) Non-pharmacological treatment options in the management of diabetes mellitus. Eur Endocrinol 14:31. https:\/\/doi.org\/10.17925\/EE.2018.14.2.31","DOI":"10.17925\/EE.2018.14.2.31"},{"key":"10562_CR128","doi-asserted-by":"publisher","DOI":"10.2337\/DC10-9990","volume":"33","author":"SR Colberg","year":"2010","unstructured":"Colberg SR, Sigal RJ, Fernhall B et al (2010) Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 33:e147. https:\/\/doi.org\/10.2337\/DC10-9990","journal-title":"Diabetes Care"},{"key":"10562_CR129","doi-asserted-by":"publisher","DOI":"10.1177\/2164956119861094","volume":"8","author":"A Gordon","year":"2019","unstructured":"Gordon A, Buch Z, Baute V, Coeytaux R (2019) Use of ayurveda in the treatment of type 2 diabetes mellitus. Glob Adv Health Med 8:2164956119861094. https:\/\/doi.org\/10.1177\/2164956119861094","journal-title":"Glob Adv Health Med"},{"key":"10562_CR130","doi-asserted-by":"publisher","DOI":"10.4103\/2225-4110.139103","volume":"4","author":"S Dwivedi","year":"2014","unstructured":"Dwivedi S, Chopra D (2014) Revisiting Terminalia arjuna \u2013 an ancient cardiovascular drug. J Tradit Complement Med 4:224. https:\/\/doi.org\/10.4103\/2225-4110.139103","journal-title":"J Tradit Complement Med"},{"key":"10562_CR131","unstructured":"Gyawali D (2017) Systematic reviews and meta-analyses on effects of ayurvedic interventions for hypercholesterolemia, hypertension, and coronary heart disease. Maharishi University of Management\u2009ProQuest Dissertations & Theses10617601, pp 1\u2013238"},{"key":"10562_CR132","doi-asserted-by":"publisher","first-page":"7118","DOI":"10.1080\/10408398.2023.2181311","volume":"64","author":"L Li","year":"2024","unstructured":"Li L, Ma P, Nirasawa S, Liu H (2024) Formation, immunomodulatory activities, and enhancement of glucosinolates and sulforaphane in broccoli sprouts: a review for maximizing the health benefits to human. Crit Rev Food Sci Nutr 64:7118\u20137148. https:\/\/doi.org\/10.1080\/10408398.2023.2181311","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10562_CR133","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/J.YJMCC.2013.01.008","volume":"57","author":"Y Bai","year":"2013","unstructured":"Bai Y, Cui W, Xin Y et al (2013) Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol 57:82\u201395. https:\/\/doi.org\/10.1016\/J.YJMCC.2013.01.008","journal-title":"J Mol Cell Cardiol"},{"key":"10562_CR134","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-811517-6.00001-5","volume":"3\u201321","author":"MK Sharif","year":"2018","unstructured":"Sharif MK, Khalid R (2018) Nutraceuticals: myths versus realities. Therapeutic Foods 3\u201321:3. https:\/\/doi.org\/10.1016\/B978-0-12-811517-6.00001-5","journal-title":"Therapeutic Foods"},{"key":"10562_CR135","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3945\/AN.114.007807","volume":"6","author":"S Fuller","year":"2015","unstructured":"Fuller S, Stephens JM (2015) Diosgenin, 4-hydroxyisoleucine, and fiber from fenugreek: mechanisms of actions and potential effects on metabolic syndrome. Adv Nutr 6:189. https:\/\/doi.org\/10.3945\/AN.114.007807","journal-title":"Adv Nutr"},{"key":"10562_CR136","doi-asserted-by":"publisher","unstructured":"Thakur M, Vasudeva N, Sharma S (2025) Diosgenin unveiled: from nutritional insights to nano applications and molecular marvels. Curr Funct Foods 03: https:\/\/doi.org\/10.2174\/0126668629330184240914131424","DOI":"10.2174\/0126668629330184240914131424"},{"key":"10562_CR137","doi-asserted-by":"publisher","unstructured":"ur-Rehman R, Riaz S, Arooj M et al (2024) Diosgenin: a potential therapeutic phytocompound for the management of atherosclerosis and other physiological disorders. Nat Prod Commun 19. https:\/\/doi.org\/10.1177\/1934578X241301228\/ASSET\/31DBB885-9A74-4A8A-9B03-F8BB13676922\/ASSETS\/IMAGES\/LARGE\/10.1177_1934578X241301228-FIG6.JPG","DOI":"10.1177\/1934578X241301228\/ASSET\/31DBB885-9A74-4A8A-9B03-F8BB13676922\/ASSETS\/IMAGES\/LARGE\/10.1177_1934578X241301228-FIG6.JPG"},{"key":"10562_CR138","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/BIOMEDICINES13020454","volume":"13","author":"P Ansari","year":"2025","unstructured":"Ansari P, Reberio AD, Ansari NJ et al (2025) Therapeutic potential of medicinal plants and their phytoconstituents in diabetes, cancer, infections, cardiovascular diseases, inflammation and gastrointestinal disorders. Biomedicines 13:454. https:\/\/doi.org\/10.3390\/BIOMEDICINES13020454","journal-title":"Biomedicines"},{"key":"10562_CR139","doi-asserted-by":"publisher","first-page":"14365","DOI":"10.3390\/IJMS232214365","volume":"23","author":"L Goya","year":"2022","unstructured":"Goya L, Kongor JE, de Pascual-Teresa S (2022) From cocoa to chocolate: effect of processing on flavanols and methylxanthines and their mechanisms of action. Int J Mol Sci 23:14365. https:\/\/doi.org\/10.3390\/IJMS232214365","journal-title":"Int J Mol Sci"},{"key":"10562_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES27217332","volume":"27","author":"S Eldesouki","year":"2022","unstructured":"Eldesouki S, Qadri R, Abu Helwa R et al (2022) Recent updates on the functional impact of Kahweol and cafestol on cancer. Molecules 27:7332. https:\/\/doi.org\/10.3390\/MOLECULES27217332","journal-title":"Molecules"},{"key":"10562_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2023.E22052","volume":"9","author":"G Singh","year":"2023","unstructured":"Singh G, Varshney V, Goyal A et al (2023) Chrysin restores the cardioprotective effect of ischemic preconditioning in diabetes-challenged rat heart. Heliyon 9:e22052. https:\/\/doi.org\/10.1016\/J.HELIYON.2023.E22052","journal-title":"Heliyon"},{"key":"10562_CR142","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.3390\/MOLECULES26134021","volume":"26","author":"J Khan","year":"2021","unstructured":"Khan J, Deb PK, Priya S et al (2021) Dietary flavonoids: cardioprotective potential with antioxidant effects and their pharmacokinetic, toxicological and therapeutic concerns. Molecules 26:4021. https:\/\/doi.org\/10.3390\/MOLECULES26134021","journal-title":"Molecules"},{"key":"10562_CR143","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/J.CLNESP.2019.07.012","volume":"34","author":"E Karimi-Nazari","year":"2019","unstructured":"Karimi-Nazari E, Nadjarzadeh A, Masoumi R et al (2019) Effect of saffron (Crocus sativus L.) on lipid profile, glycemic indices and antioxidant status among overweight\/obese prediabetic individuals: a double-blinded, randomized controlled trial. Clin Nutr ESPEN 34:130\u2013136. https:\/\/doi.org\/10.1016\/J.CLNESP.2019.07.012","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"10562_CR144","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/0974-8490.197797","volume":"9","author":"J Vinholes","year":"2017","unstructured":"Vinholes J, Vizzotto M (2017) Synergisms in alpha-glucosidase inhibition and antioxidant activity of Camellia sinensis L. Kuntze and Eugenia uniflora L. ethanolic extracts. Pharmacogn Res 9:101. https:\/\/doi.org\/10.4103\/0974-8490.197797","journal-title":"Pharmacogn Res"},{"key":"10562_CR145","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ctim.2019.02.014","volume":"43","author":"S Asadi","year":"2019","unstructured":"Asadi S, Gholami MS, Siassi F et al (2019) Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: a randomized double-blind placebo- controlled clinical trial. Complement Ther Med 43:253\u2013260. https:\/\/doi.org\/10.1016\/j.ctim.2019.02.014","journal-title":"Complement Ther Med"},{"key":"10562_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2018.12.008","volume":"148","author":"M Niroomand","year":"2019","unstructured":"Niroomand M, Fotouhi A, Irannejad N, Hosseinpanah F (2019) Does high-dose vitamin D supplementation impact insulin resistance and risk of development of diabetes in patients with pre-diabetes? A double-blind randomized clinical trial. Diabetes Res Clin Pract 148:1\u20139. https:\/\/doi.org\/10.1016\/j.diabres.2018.12.008","journal-title":"Diabetes Res Clin Pract"},{"key":"10562_CR147","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4172\/2155-6156.1000740","volume":"08","author":"SA Ezekwe","year":"2017","unstructured":"Ezekwe SA, Chikezie PC (2017) GC-MS analysis, hypoglycemic activity of aqueous root extract of Carica papaya and its effects on blood lipid profile and hepatorenal tissues biomarkers of diabetic rats. J Diabetes Metab 08:740\u2013748. https:\/\/doi.org\/10.4172\/2155-6156.1000740","journal-title":"J Diabetes Metab"},{"key":"10562_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/NU8050250","volume":"8","author":"D Bonnefont-Rousselot","year":"2016","unstructured":"Bonnefont-Rousselot D (2016) Resveratrol and cardiovascular diseases. Nutrients 8:250. https:\/\/doi.org\/10.3390\/NU8050250","journal-title":"Nutrients"},{"key":"10562_CR149","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2174\/1570179420666230607124949\/CITE\/REFWORKS","volume":"21","author":"MH Shahrajabian","year":"2024","unstructured":"Shahrajabian MH, Sun W (2024) The golden spice for life: turmeric with the pharmacological benefits of curcuminoids components, including curcumin, bisdemethoxycurcumin, and demethoxycurcumins. Curr Org Synth 21:665\u2013683. https:\/\/doi.org\/10.2174\/1570179420666230607124949\/CITE\/REFWORKS","journal-title":"Curr Org Synth"},{"key":"10562_CR150","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/10408398.2018.1552244","volume":"60","author":"SS Patel","year":"2019","unstructured":"Patel SS, Acharya A, Ray RS (2019) Cellular and molecular mechanisms of curcumin in prevention and treatment of disease. Crit Rev Food Sci Nutr 60:887\u2013939. https:\/\/doi.org\/10.1080\/10408398.2018.1552244","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10562_CR151","doi-asserted-by":"publisher","first-page":"820806","DOI":"10.3389\/FPHAR.2022.820806\/XML","volume":"13","author":"S Fuloria","year":"2022","unstructured":"Fuloria S, Mehta J, Chandel A et al (2022) A comprehensive review on the therapeutic potential of Curcuma longa Linn. in relation to its major active constituent curcumin. Front Pharmacol 13:820806. https:\/\/doi.org\/10.3389\/FPHAR.2022.820806\/XML","journal-title":"Front Pharmacol"},{"key":"10562_CR152","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1681\/ASN.2011060629","volume":"22","author":"MA Reddy","year":"2011","unstructured":"Reddy MA, Natarajan R (2011) Epigenetics in diabetic kidney disease. J Am Soc Nephrol 22:2182\u20132185. https:\/\/doi.org\/10.1681\/ASN.2011060629","journal-title":"J Am Soc Nephrol"},{"key":"10562_CR153","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/EURHEARTJ\/EHY597","volume":"40","author":"V Lionetti","year":"2019","unstructured":"Lionetti V, Tuana BS, Casieri V et al (2019) Importance of functional food compounds in cardioprotection through action on the epigenome. Eur Heart J 40:575\u2013582. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHY597","journal-title":"Eur Heart J"},{"key":"10562_CR154","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/137.1.223s","author":"M Fang","year":"2007","unstructured":"Fang M, Chen D, Yang CS (2007) Dietary polyphenols may affect DNA methylation. J Nutr. https:\/\/doi.org\/10.1093\/jn\/137.1.223s","journal-title":"J Nutr"},{"key":"10562_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/FGENE.2019.00514","author":"FU Hassan","year":"2019","unstructured":"Hassan FU, Rehman MSU, Khan MS et al (2019) Curcumin as an alternative epigenetic modulator: mechanism of action and potential effects. Front Genet. https:\/\/doi.org\/10.3389\/FGENE.2019.00514","journal-title":"Front Genet"},{"key":"10562_CR156","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jnutbio.2015.06.006","volume":"26","author":"PK Bagul","year":"2015","unstructured":"Bagul PK, Deepthi N, Sultana R, Banerjee SK (2015) Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3. J Nutr Biochem 26:1298\u20131307. https:\/\/doi.org\/10.1016\/j.jnutbio.2015.06.006","journal-title":"J Nutr Biochem"},{"key":"10562_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13020147","author":"K Barali\u0107","year":"2024","unstructured":"Barali\u0107 K, \u017divanovi\u0107 J, Mari\u0107 \u0110 (2024) Sulforaphane\u2014a compound with potential health benefits for disease prevention and treatment: insights from pharmacological and toxicological experimental studies. Antioxidants. https:\/\/doi.org\/10.3390\/antiox13020147","journal-title":"Antioxidants"},{"key":"10562_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/S13148-024-01667-1","author":"X Ma","year":"2024","unstructured":"Ma X, Mei S, Wuyun Q (2024) Epigenetics in diabetic cardiomyopathy. Clin Epigenetics. https:\/\/doi.org\/10.1186\/S13148-024-01667-1","journal-title":"Clin Epigenetics"},{"key":"10562_CR159","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.3390\/MOLECULES25204613","volume":"25","author":"B Yang","year":"2020","unstructured":"Yang B, Dong Y, Wang F, Zhang Y (2020) Nanoformulations to enhance the bioavailability and physiological functions of polyphenols. Molecules 25:4613. https:\/\/doi.org\/10.3390\/MOLECULES25204613","journal-title":"Molecules"},{"key":"10562_CR160","doi-asserted-by":"publisher","unstructured":"Ansari P, Hannon-Fletcher MP, Flatt PR, Abdel-Wahab YHA (2021) Effects of 22 traditional anti-diabetic medicinal plants on DPP-IV enzyme activity and glucose homeostasis in high-fat fed obese diabetic rats. Biosci Rep 41:. https:\/\/doi.org\/10.1042\/BSR20203824\/227539","DOI":"10.1042\/BSR20203824\/227539"},{"key":"10562_CR161","doi-asserted-by":"publisher","unstructured":"Faruk Khan MO (2024) Medicinal chemistry of drugs affecting cardiovascular and endocrine systems. 3:. https:\/\/doi.org\/10.2174\/97898151797291240301","DOI":"10.2174\/97898151797291240301"},{"key":"10562_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/J.METABOL.2022.155160","volume":"130","author":"G Schernthaner","year":"2022","unstructured":"Schernthaner G, Brand K, Bailey CJ (2022) Metformin and the heart: update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism 130:155160. https:\/\/doi.org\/10.1016\/J.METABOL.2022.155160","journal-title":"Metabolism"},{"key":"10562_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2024.107264","volume":"206","author":"D Jia","year":"2024","unstructured":"Jia D, Liu L, Liu W (2024) Copper metabolism and its role in diabetic complications: a review. Pharmacol Res 206:107264. https:\/\/doi.org\/10.1016\/J.PHRS.2024.107264","journal-title":"Pharmacol Res"},{"key":"10562_CR164","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ (2016) The cardiovascular biology of glucagon-like peptide-1. Cell Metab 24:15\u201330. https:\/\/doi.org\/10.1016\/j.cmet.2016.06.009","journal-title":"Cell Metab"},{"key":"10562_CR165","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/DOM.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ (2018) Incretin hormones: their role in health and disease. Diabetes Obes Metab 20:5\u201321. https:\/\/doi.org\/10.1111\/DOM.13129","journal-title":"Diabetes Obes Metab"},{"key":"10562_CR166","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1124\/jpet.106.100982","volume":"317","author":"T Zhao","year":"2006","unstructured":"Zhao T, Parikh P, Bhashyam S et al (2006) Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317:1106\u20131113. https:\/\/doi.org\/10.1124\/jpet.106.100982","journal-title":"J Pharmacol Exp Ther"},{"key":"10562_CR167","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10562_CR168","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMOA1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMOA1607141","journal-title":"N Engl J Med"},{"issue":"4","key":"10562_CR169","doi-asserted-by":"publisher","DOI":"10.1002\/ADVS.202409781","volume":"12","author":"S Tian","year":"2025","unstructured":"Tian S, Zhou S, Wu W et al (2025) GLP-1 receptor agonists alleviate diabetic kidney injury via \u03b2-klotho-mediated ferroptosis inhibition. Adv Sci 12(4):2409781. https:\/\/doi.org\/10.1002\/ADVS.202409781","journal-title":"Adv Sci"},{"key":"10562_CR170","doi-asserted-by":"publisher","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. Drug Ther Bull 54:101. https:\/\/doi.org\/10.1056\/NEJMOA1603827","DOI":"10.1056\/NEJMOA1603827"},{"key":"10562_CR171","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"10562_CR172","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMOA2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMOA2032183","journal-title":"N Engl J Med"},{"key":"10562_CR173","doi-asserted-by":"publisher","DOI":"10.1152\/AJPCELL.00093.2016","volume":"311","author":"T Zhou","year":"2016","unstructured":"Zhou T, Zhang M, Zhao L et al (2016) Activation of Nrf2 contributes to the protective effect of exendin-4 against angiotensin II-induced vascular smooth muscle cell senescence. Am J Physiol Cell Physiol 311:C572\u2013C582. https:\/\/doi.org\/10.1152\/AJPCELL.00093.2016","journal-title":"Am J Physiol Cell Physiol"},{"key":"10562_CR174","doi-asserted-by":"publisher","DOI":"10.1152\/AJPHEART.00347.2005","author":"LA Nikolaidis","year":"2005","unstructured":"Nikolaidis LA, Elahi D, Shen YT, Shannon RP (2005) Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. https:\/\/doi.org\/10.1152\/AJPHEART.00347.2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10562_CR175","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/JAMA.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM et al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316:500\u2013508. https:\/\/doi.org\/10.1001\/JAMA.2016.10260","journal-title":"JAMA"},{"key":"10562_CR176","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/EJHF.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19:69\u201377. https:\/\/doi.org\/10.1002\/EJHF.657","journal-title":"Eur J Heart Fail"},{"key":"10562_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2024.107515","volume":"210","author":"A Rostami","year":"2024","unstructured":"Rostami A, Palomer X, Pizarro-Delgado J et al (2024) PPAR\u03b2\/\u03b4 prevents inflammation and fibrosis during diabetic cardiomyopathy. Pharmacol Res 210:107515. https:\/\/doi.org\/10.1016\/J.PHRS.2024.107515","journal-title":"Pharmacol Res"},{"key":"10562_CR178","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/APHA.12604","volume":"216","author":"H Poudyal","year":"2016","unstructured":"Poudyal H (2016) Mechanisms for the cardiovascular effects of glucagon-like peptide-1. Acta Physiol 216:277\u2013313. https:\/\/doi.org\/10.1111\/APHA.12604","journal-title":"Acta Physiol"},{"issue":"2","key":"10562_CR179","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0828-282x(10)70010-6","volume":"26","author":"PE Szmitko","year":"2010","unstructured":"Szmitko PE, Leiter LA, Verma S (2010) The incretin system and cardiometabolic disease. Can J Cardiol 26(2):87\u201395. https:\/\/doi.org\/10.1016\/s0828-282x(10)70010-6","journal-title":"Can J Cardiol"},{"key":"10562_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-020-01071-Y\/TABLES\/5","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni L, Yuan C, Chen G et al (2020) SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol 19:1\u201310. https:\/\/doi.org\/10.1186\/S12933-020-01071-Y\/TABLES\/5","journal-title":"Cardiovasc Diabetol"},{"key":"10562_CR181","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/MOLECULES26237213","volume":"26","author":"A Pawlos","year":"2021","unstructured":"Pawlos A, Broncel M, Wo\u017aniak E, Gorzelak-Pabi\u015b P (2021) Neuroprotective effect of SGLT2 inhibitors. Molecules 26:7213. https:\/\/doi.org\/10.3390\/MOLECULES26237213","journal-title":"Molecules"},{"key":"10562_CR182","doi-asserted-by":"publisher","DOI":"10.36628\/IJHF.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"Talha KM, Anker SD, Butler J (2023) SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail 5:82. https:\/\/doi.org\/10.36628\/IJHF.2022.0030","journal-title":"Int J Heart Fail"},{"key":"10562_CR183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-024-02490-X","volume":"23","author":"A Fiordelisi","year":"2024","unstructured":"Fiordelisi A, Cerasuolo FA, Avvisato R et al (2024) L-arginine supplementation as mitochondrial therapy in diabetic cardiomyopathy. Cardiovasc Diabetol 23:1\u201314. https:\/\/doi.org\/10.1186\/S12933-024-02490-X","journal-title":"Cardiovasc Diabetol"},{"key":"10562_CR184","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJMOA1504720\/SUPPL_FILE\/NEJMOA1504720_DISCLOSURES.PDF","volume":"13","author":"S Steiner","year":"2016","unstructured":"Steiner S (2016) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Z Gefassmed 13:17\u201318. https:\/\/doi.org\/10.1056\/NEJMOA1504720\/SUPPL_FILE\/NEJMOA1504720_DISCLOSURES.PDF","journal-title":"Z Gefassmed"},{"key":"10562_CR185","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMOA2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMOA2206286","journal-title":"N Engl J Med"},{"key":"10562_CR186","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMOA2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMOA2022190","journal-title":"N Engl J Med"},{"key":"10562_CR187","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMOA2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMOA2107038","journal-title":"N Engl J Med"},{"key":"10562_CR188","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","volume":"139","author":"D Fitchett","year":"2019","unstructured":"Fitchett D, Inzucchi SE, Cannon CP et al (2019) Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation 139:1384\u20131395. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037778","journal-title":"Circulation"},{"key":"10562_CR189","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/J.JACC.2023.08.026","volume":"82","author":"S Chatur","year":"2023","unstructured":"Chatur S, Vaduganathan M, Claggett BL et al (2023) Dapagliflozin in patients with heart failure and deterioration in renal function. J Am Coll Cardiol 82:1854\u20131863. https:\/\/doi.org\/10.1016\/J.JACC.2023.08.026","journal-title":"J Am Coll Cardiol"},{"key":"10562_CR190","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/JPET.123.002037","volume":"391","author":"HM Hashiesh","year":"2024","unstructured":"Hashiesh HM, Azimullah S, Meeran MFN et al (2024) Cannabinoid 2 receptor activation protects against diabetic cardiomyopathy through inhibition of AGE\/RAGE-induced oxidative stress, fibrosis, and inflammasome activation. J Pharmacol Exp Ther 391:241\u2013257. https:\/\/doi.org\/10.1124\/JPET.123.002037","journal-title":"J Pharmacol Exp Ther"},{"key":"10562_CR191","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/J.1463-1326.2008.00853.X","volume":"10","author":"K Aaboe","year":"2008","unstructured":"Aaboe K, Krarup T, Madsbad S, Holst JJ (2008) GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab 10:994\u20131003. https:\/\/doi.org\/10.1111\/J.1463-1326.2008.00853.X","journal-title":"Diabetes Obes Metab"},{"key":"10562_CR192","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.2147\/DDDT.S269514","volume":"14","author":"N Li","year":"2020","unstructured":"Li N, Zhou H (2020) Sglt2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy. Drug Des Devel Ther 14:4775\u20134788. https:\/\/doi.org\/10.2147\/DDDT.S269514","journal-title":"Drug Des Devel Ther"},{"key":"10562_CR193","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/S10557-017-6725-2","volume":"31","author":"Y Ye","year":"2017","unstructured":"Ye Y, Bajaj M, Yang HC et al (2017) SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 31:119\u2013132. https:\/\/doi.org\/10.1007\/S10557-017-6725-2","journal-title":"Cardiovasc Drugs Ther"},{"key":"10562_CR194","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2007.4.126","volume":"4","author":"HW De Valk","year":"2007","unstructured":"De Valk HW (2007) DPP-4 inhibitors and combined treatment in type 2 diabetes: re-evaluation of clinical success and safety. Rev Diabet Stud 4:126. https:\/\/doi.org\/10.1900\/RDS.2007.4.126","journal-title":"Rev Diabet Stud"},{"key":"10562_CR195","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/5584_2017_105","volume":"1067","author":"N Alonso","year":"2017","unstructured":"Alonso N, Moliner P, Mauricio D (2017) Pathogenesis, clinical features and treatment of diabetic cardiomyopathy. Adv Exp Med Biol 1067:197\u2013217. https:\/\/doi.org\/10.1007\/5584_2017_105","journal-title":"Adv Exp Med Biol"},{"key":"10562_CR196","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1517\/13543784.15.6.625","volume":"15","author":"BMY Cheung","year":"2006","unstructured":"Cheung BMY (2006) Therapeutic potential of angiotensin receptor blockers in hypertension. Expert Opin Investig Drugs 15:625\u2013635. https:\/\/doi.org\/10.1517\/13543784.15.6.625","journal-title":"Expert Opin Investig Drugs"},{"key":"10562_CR197","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0735-1097(01)01229-3","volume":"37","author":"ME Khalil","year":"2001","unstructured":"Khalil ME, Basher AW, Brown EJ, Alhaddad IA (2001) A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol 37:1757\u20131764. https:\/\/doi.org\/10.1016\/S0735-1097(01)01229-3","journal-title":"J Am Coll Cardiol"},{"key":"10562_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2020.173114","volume":"878","author":"E Gallego-Colon","year":"2020","unstructured":"Gallego-Colon E, Daum A, Yosefy C (2020) Statins and PCSK9 inhibitors: a new lipid-lowering therapy. Eur J Pharmacol 878:173114. https:\/\/doi.org\/10.1016\/J.EJPHAR.2020.173114","journal-title":"Eur J Pharmacol"},{"key":"10562_CR199","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X19666230111143901","volume":"19","author":"N Johri","year":"2023","unstructured":"Johri N, Matreja PS, Maurya A et al (2023) Role of \u03b2-blockers in preventing heart failure and major adverse cardiac events post myocardial infarction. Curr Cardiol Rev 19:e110123212591. https:\/\/doi.org\/10.2174\/1573403X19666230111143901","journal-title":"Curr Cardiol Rev"},{"key":"10562_CR200","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/SJ.BJP.0707452","volume":"153","author":"CE Quinn","year":"2007","unstructured":"Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE (2007) Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153:636. https:\/\/doi.org\/10.1038\/SJ.BJP.0707452","journal-title":"Br J Pharmacol"},{"key":"10562_CR201","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1054-3589(10)59003-3","volume":"59","author":"C Thollon","year":"2010","unstructured":"Thollon C, Vilaine JP (2010) If inhibition in cardiovascular diseases. Adv Pharmacol 59:53\u201392. https:\/\/doi.org\/10.1016\/S1054-3589(10)59003-3","journal-title":"Adv Pharmacol"},{"key":"10562_CR202","doi-asserted-by":"publisher","DOI":"10.15420\/ECR.2022.10","volume":"18","author":"DKSC Putri","year":"2023","unstructured":"Putri DKSC, Andrianto A, Al-Farabi MJ et al (2023) Efficacy of ranolazine to improve diastolic performance in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur Cardiol Rev 18:e02. https:\/\/doi.org\/10.15420\/ECR.2022.10","journal-title":"Eur Cardiol Rev"},{"key":"10562_CR203","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/J.IJCHV.2014.03.005","volume":"3","author":"E Vizzardi","year":"2014","unstructured":"Vizzardi E, Regazzoni V, Caretta G et al (2014) Mineralocorticoid receptor antagonist in heart failure: past, present and future perspectives. IJC Heart & Vessels 3:6\u201314. https:\/\/doi.org\/10.1016\/J.IJCHV.2014.03.005","journal-title":"IJC Heart & Vessels"},{"key":"10562_CR204","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIOX13101228","volume":"13","author":"F Superti","year":"2024","unstructured":"Superti F, Russo R (2024) Alpha-lipoic acid: biological mechanisms and health benefits. Antioxidants 13:1228. https:\/\/doi.org\/10.3390\/ANTIOX13101228","journal-title":"Antioxidants"},{"key":"10562_CR205","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","volume":"6","author":"MHA Muskiet","year":"2018","unstructured":"Muskiet MHA, Tonneijck L, Huang Y et al (2018) Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 6:859\u2013869. https:\/\/doi.org\/10.1016\/S2213-8587(18)30268-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10562_CR206","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/J.1751-7176.2011.00449.X","volume":"13","author":"WA Hsueh","year":"2011","unstructured":"Hsueh WA, Wyne K (2011) Renin-angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich) 13:224. https:\/\/doi.org\/10.1111\/J.1751-7176.2011.00449.X","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10562_CR207","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/BIOMEDICINES12040765","volume":"12","author":"E Radzioch","year":"2024","unstructured":"Radzioch E, D\u0105bek B, Balcerczyk-Lis M et al (2024) Diabetic cardiomyopathy\u2014from basics through diagnosis to treatment. Biomedicines 12:765. https:\/\/doi.org\/10.3390\/BIOMEDICINES12040765","journal-title":"Biomedicines"},{"key":"10562_CR208","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/J.JPHS.2019.01.016","volume":"139","author":"SG Tang","year":"2019","unstructured":"Tang SG, Liu XY, Wang SP et al (2019) Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2\/TRPC3-induced oxidative stress. J Pharmacol Sci 139:311\u2013318. https:\/\/doi.org\/10.1016\/J.JPHS.2019.01.016","journal-title":"J Pharmacol Sci"},{"key":"10562_CR209","doi-asserted-by":"publisher","unstructured":"(2025) Corrigendum to \u201cLiquiritin alleviates depression\u2010like behavior in CUMS mice by inhibiting oxidative stress and NLRP3 inflammasome in hippocampus\". Evidence-Based Complementary and Alternative Medicine 2025. https:\/\/doi.org\/10.1155\/ECAM\/9768027","DOI":"10.1155\/ECAM\/9768027"},{"key":"10562_CR210","doi-asserted-by":"publisher","unstructured":"Tan Y, Zhang Z, Zheng C et al (2020) Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol 17:585\u2013607. https:\/\/doi.org\/10.1038\/s41569-020-0339-2","DOI":"10.1038\/s41569-020-0339-2"},{"key":"10562_CR211","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3390\/IJMS25042104","volume":"5","author":"A Liuiz\u0117","year":"2024","unstructured":"Liuiz\u0117 A, Mongirdien\u0117 A (2024) TGF-\u03b2 isoforms and GDF-15 in the development and progression of atherosclerosis. International Journal of Molecular Sciences 5:2104. https:\/\/doi.org\/10.3390\/IJMS25042104","journal-title":"International Journal of Molecular Sciences"},{"key":"10562_CR212","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/RHEUMATOLOGY\/KEAB277","volume":"61","author":"MG Tektonidou","year":"2021","unstructured":"Tektonidou MG, Papassotiriou I, Sfikakis PP (2021) Growth differentiation factor 15 (GDF-15) as potential cardiovascular risk biomarker in antiphospholipid syndrome. Rheumatology 61:394\u2013399. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAB277","journal-title":"Rheumatology"},{"key":"10562_CR213","doi-asserted-by":"publisher","first-page":"542657","DOI":"10.3389\/FIMMU.2020.00951\/XML","volume":"11","author":"J Wischhusen","year":"2020","unstructured":"Wischhusen J, Melero I, Fridman WH (2020) Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front Immunol 11:542657. https:\/\/doi.org\/10.3389\/FIMMU.2020.00951\/XML","journal-title":"Front Immunol"},{"issue":"4","key":"10562_CR214","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/S11897-023-00610-4","volume":"20","author":"K Sawalha","year":"2023","unstructured":"Sawalha K, Norgard NB, Drees BM, L\u00f3pez-Candales A (2023) Growth differentiation factor 15 (GDF-15), a new biomarker in heart failure management. Curr Heart Fail Rep 20(4):287\u2013299. https:\/\/doi.org\/10.1007\/S11897-023-00610-4","journal-title":"Curr Heart Fail Rep"},{"key":"10562_CR215","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22168889","volume":"22","author":"L Rochette","year":"2021","unstructured":"Rochette L, Dogon G, Zeller M et al (2021) GDF15 and cardiac cells: current concepts and new insights. Int J Mol Sci 22:8889. https:\/\/doi.org\/10.3390\/IJMS22168889","journal-title":"Int J Mol Sci"},{"key":"10562_CR216","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/490842","volume":"2015","author":"R Adela","year":"2015","unstructured":"Adela R, Banerjee SK (2015) GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res 2015:490842. https:\/\/doi.org\/10.1155\/2015\/490842","journal-title":"J Diabetes Res"},{"key":"10562_CR217","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/J.AMJCARD.2014.06.020","volume":"114","author":"A Dominguez-Rodriguez","year":"2014","unstructured":"Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P (2014) Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 114:890\u2013894. https:\/\/doi.org\/10.1016\/J.AMJCARD.2014.06.020","journal-title":"Am J Cardiol"},{"key":"10562_CR218","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1055\/A-0983-1673\/ID\/R12-2018-0535-DIA-0017\/BIB","volume":"129","author":"C Uysal","year":"2021","unstructured":"Uysal C, Arslan D, Buyukinan M et al (2021) Growth differentiation factor-15 level and tissue Doppler echocardiography as a tool in identification of cardiac effects in the children with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 129:574\u2013580. https:\/\/doi.org\/10.1055\/A-0983-1673\/ID\/R12-2018-0535-DIA-0017\/BIB","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10562_CR219","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/J.EJIM.2011.08.022","volume":"23","author":"S Montoro-Garc\u00eda","year":"2012","unstructured":"Montoro-Garc\u00eda S, Hern\u00e1ndez-Romero D, Jover E et al (2012) Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. Eur J Intern Med 23:169\u2013174. https:\/\/doi.org\/10.1016\/J.EJIM.2011.08.022","journal-title":"Eur J Intern Med"},{"key":"10562_CR220","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/EHF2.12722","volume":"7","author":"A Kalayci","year":"2020","unstructured":"Kalayci A, Peacock WF, Nagurney JT et al (2020) Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure. ESC Heart Fail 7:1664\u20131675. https:\/\/doi.org\/10.1002\/EHF2.12722","journal-title":"ESC Heart Fail"},{"key":"10562_CR221","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/J.AMJCARD.2014.08.018","volume":"114","author":"PU Gandhi","year":"2014","unstructured":"Gandhi PU, Gaggin HK, Sheftel AD et al (2014) Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? Am J Cardiol 114:1543\u20131549. https:\/\/doi.org\/10.1016\/J.AMJCARD.2014.08.018","journal-title":"Am J Cardiol"},{"issue":"1","key":"10562_CR222","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1152\/PHYSREV.00002.2018","volume":"99","author":"E Bloise","year":"2019","unstructured":"Bloise E, Ciarmela P, Dela Cruz C et al (2019) Activin A in mammalian physiology. Physiol Rev 99(1):739\u2013780. https:\/\/doi.org\/10.1152\/PHYSREV.00002.2018","journal-title":"Physiol Rev"},{"key":"10562_CR223","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/CVR\/CVT173","volume":"100","author":"M Blumensatt","year":"2013","unstructured":"Blumensatt M, Greulich S, Herzfeld De Wiza D et al (2013) Activin a impairs insulin action in cardiomyocytes via up-regulation of miR-143. Cardiovasc Res 100:201\u2013210. https:\/\/doi.org\/10.1093\/CVR\/CVT173","journal-title":"Cardiovasc Res"},{"key":"10562_CR224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13098-023-00998-Y","volume":"15","author":"J Deng","year":"2023","unstructured":"Deng J, Yan F, Tian J et al (2023) Potential clinical biomarkers and perspectives in diabetic cardiomyopathy. Diabetol Metab Syndr 15:1\u201315. https:\/\/doi.org\/10.1186\/S13098-023-00998-Y","journal-title":"Diabetol Metab Syndr"},{"key":"10562_CR225","doi-asserted-by":"publisher","unstructured":"Chen J, Wei X, Zhang Q et al (2021) TMR modern herbal medicine progress of ubiquitin-proteasome system in the pathophysiology of heart failure and the intervention of traditional Chinese medicine. https:\/\/doi.org\/10.53388\/MHM2021B0420001","DOI":"10.53388\/MHM2021B0420001"},{"key":"10562_CR226","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-3-030-38266-7_12","volume":"1233","author":"D Batista-Almeida","year":"2020","unstructured":"Batista-Almeida D, Martins-Marques T, Ribeiro-Rodrigues T, Girao H (2020) The role of proteostasis in the regulation of cardiac intercellular communication. Adv Exp Med Biol 1233:279\u2013302. https:\/\/doi.org\/10.1007\/978-3-030-38266-7_12","journal-title":"Adv Exp Med Biol"},{"key":"10562_CR227","doi-asserted-by":"publisher","DOI":"10.3390\/MEDICINA61040582","volume":"61","author":"S Yan\u0131k \u00c7olak","year":"2025","unstructured":"Yan\u0131k \u00c7olak S, Anda\u00e7 B, \u00d6zg\u00fcn E et al (2025) The relationship between serum MG53 levels and the presence of metabolic syndrome and its components. Medicina (B Aires) 61:582. https:\/\/doi.org\/10.3390\/MEDICINA61040582","journal-title":"Medicina (B Aires)"},{"key":"10562_CR228","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13511","volume":"16","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zheng Z, Wu S, Zhu J (2024) Ubiquitin-conjugating enzyme E2 for regulating autophagy in diabetic cardiomyopathy: a mini-review. J Diabetes 16:e13511. https:\/\/doi.org\/10.1111\/1753-0407.13511","journal-title":"J Diabetes"},{"key":"10562_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOCEL.2019.105659","volume":"118","author":"R Menghini","year":"2020","unstructured":"Menghini R, Casagrande V, Iuliani G (2020) Metabolic aspects of cardiovascular diseases: is FoxO1 a player or a target? Int J Biochem Cell Biol 118:105659. https:\/\/doi.org\/10.1016\/J.BIOCEL.2019.105659","journal-title":"Int J Biochem Cell Biol"},{"key":"10562_CR230","doi-asserted-by":"publisher","DOI":"10.1105\/TPC.13.11.2385","volume":"13","author":"NA Eckardt","year":"2001","unstructured":"Eckardt NA (2001) Transcription factors dial 14\u20133-3 for nuclear shuttle. Plant Cell 13:2385. https:\/\/doi.org\/10.1105\/TPC.13.11.2385","journal-title":"Plant Cell"},{"key":"10562_CR231","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-3-030-49844-3_8","volume":"1275","author":"AB Engin","year":"2021","unstructured":"Engin AB, Engin A (2021) Protein kinases signaling in pancreatic beta-cells death and type 2 diabetes. Adv Exp Med Biol 1275:195\u2013227. https:\/\/doi.org\/10.1007\/978-3-030-49844-3_8","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10562_CR232","doi-asserted-by":"publisher","first-page":"826","DOI":"10.14336\/AD.2020.1217","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Fan J, Li H (2021) CD36 signaling in diabetic cardiomyopathy. Aging Dis 12:826. https:\/\/doi.org\/10.14336\/AD.2020.1217","journal-title":"Aging Dis"},{"key":"10562_CR233","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI60329","volume":"122","author":"PK Battiprolu","year":"2012","unstructured":"Battiprolu PK, Hojayev B, Jiang N et al (2012) Metabolic stress\u2013induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 122:1109. https:\/\/doi.org\/10.1172\/JCI60329","journal-title":"J Clin Invest"},{"key":"10562_CR234","doi-asserted-by":"publisher","unstructured":"Palmieri M, Pesce A, Tagliaferro M, Ponti D (2023) The signaling of neuregulin-epidermal growth factor receptors and its impact on the nervous system. Neuroglia 4:253\u2013274. https:\/\/doi.org\/10.3390\/NEUROGLIA4040018","DOI":"10.3390\/NEUROGLIA4040018"},{"key":"10562_CR235","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13205038","volume":"13","author":"D Rosas","year":"2021","unstructured":"Rosas D, Raez LE, Russo A, Rolfo C (2021) Neuregulin 1 gene (NRG1). A potentially new targetable alteration for the treatment of lung cancer. Cancers 13:5038. https:\/\/doi.org\/10.3390\/CANCERS13205038","journal-title":"Cancers"},{"key":"10562_CR236","doi-asserted-by":"publisher","unstructured":"Rupert CE, Coulombe KLK (2015) The roles of neuregulin-1 in cardiac development, homeostasis, and disease. Biomark Insights 2015:1\u20139. https:\/\/doi.org\/10.4137\/BMI.S20061\/ASSET\/435A84AE-404B-42EF-A14F-CB434FB3FAAC\/ASSETS\/IMAGES\/LARGE\/10.4137_BMI.S20061-FIG1.JPG","DOI":"10.4137\/BMI.S20061\/ASSET\/435A84AE-404B-42EF-A14F-CB434FB3FAAC\/ASSETS\/IMAGES\/LARGE\/10.4137_BMI.S20061-FIG1.JPG"},{"key":"10562_CR237","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2022.945206","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wei J, Zhang P et al (2022) Neuregulin-1, a potential therapeutic target for cardiac repair. Front Pharmacol 13:945206. https:\/\/doi.org\/10.3389\/FPHAR.2022.945206","journal-title":"Front Pharmacol"},{"issue":"3","key":"10562_CR238","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/S10741-022-10271-5","volume":"28","author":"S Rupee","year":"2022","unstructured":"Rupee S, Rupee K, Singh RB et al (2022) Diabetes-induced chronic heart failure is due to defects in calcium transporting and regulatory contractile proteins: cellular and molecular evidence. Heart Fail Rev 28(3):627\u2013644. https:\/\/doi.org\/10.1007\/S10741-022-10271-5","journal-title":"Heart Fail Rev"},{"key":"10562_CR239","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.CCA.2020.04.011","volume":"507","author":"E Homsak","year":"2020","unstructured":"Homsak E, Gruson D (2020) Soluble ST2: a complex and diverse role in several diseases. Clin Chim Acta 507:75\u201387. https:\/\/doi.org\/10.1016\/J.CCA.2020.04.011","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10562_CR240","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4239\/WJD.V12.I6.685","volume":"12","author":"M Kumric","year":"2021","unstructured":"Kumric M, Kurir TT, Borovac JA, Bozic J (2021) Role of novel biomarkers in diabetic cardiomyopathy. World J Diabetes 12(6):685. https:\/\/doi.org\/10.4239\/WJD.V12.I6.685","journal-title":"World J Diabetes"},{"key":"10562_CR241","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/J.JACC.2019.08.1039","volume":"74","author":"A Aimo","year":"2019","unstructured":"Aimo A, Januzzi JL, Bayes-Genis A et al (2019) Clinical and prognostic significance of sST2 in heart failure: JACC Review Topic of the Week. J Am Coll Cardiol 74:2193\u20132203. https:\/\/doi.org\/10.1016\/J.JACC.2019.08.1039","journal-title":"J Am Coll Cardiol"},{"key":"10562_CR242","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-10-101\/TABLES\/3","volume":"10","author":"E Fousteris","year":"2011","unstructured":"Fousteris E, Melidonis A, Panoutsopoulos G et al (2011) Toll\/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol 10:1\u20137. https:\/\/doi.org\/10.1186\/1475-2840-10-101\/TABLES\/3","journal-title":"Cardiovasc Diabetol"},{"key":"10562_CR243","doi-asserted-by":"publisher","first-page":"1124613","DOI":"10.3389\/FENDO.2023.1124613\/XML","volume":"14","author":"MT Macvanin","year":"2023","unstructured":"Macvanin MT, Gluvic Z, Radovanovic J et al (2023) Diabetic cardiomyopathy: the role of microRNAs and long non-coding RNAs. Front Endocrinol (Lausanne) 14:1124613. https:\/\/doi.org\/10.3389\/FENDO.2023.1124613\/XML","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10562_CR244","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2020.612722\/BIBTEX","volume":"11","author":"AK Rai","year":"2021","unstructured":"Rai AK, Lee B, Gomez R et al (2021) Current status and potential therapeutic strategies for using non-coding RNA to treat diabetic cardiomyopathy. Front Physiol 11:612722. https:\/\/doi.org\/10.3389\/FPHYS.2020.612722\/BIBTEX","journal-title":"Front Physiol"},{"key":"10562_CR245","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1310265","volume":"2017","author":"GE Gilca","year":"2017","unstructured":"Gilca GE, Stefanescu G, Badulescu O et al (2017) Diabetic cardiomyopathy: current approach and potential diagnostic and therapeutic targets. J Diabetes Res 2017:1310265. https:\/\/doi.org\/10.1155\/2017\/1310265","journal-title":"J Diabetes Res"},{"key":"10562_CR246","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6143129","author":"LE Le\u00f3n","year":"2016","unstructured":"Le\u00f3n LE, Rani S, Fernandez M (2016) Subclinical detection of diabetic cardiomyopathy with microRNAs: challenges and perspectives. J Diabetes Res. https:\/\/doi.org\/10.1155\/2016\/6143129","journal-title":"J Diabetes Res"},{"key":"10562_CR247","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-021-01245-2","volume":"20","author":"D Jakubik","year":"2021","unstructured":"Jakubik D, Fitas A, Eyileten C et al (2021) Micrornas and long non-coding rnas in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics. Cardiovasc Diabetol 20:1\u201329. https:\/\/doi.org\/10.1186\/S12933-021-01245-2","journal-title":"Cardiovasc Diabetol"},{"key":"10562_CR248","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/J.BBRC.2016.06.051","volume":"477","author":"Y Qiao","year":"2016","unstructured":"Qiao Y, Zhao Y, Liu Y (2016) Mir-483-3p regulates hyperglycaemia-induced cardiomyocyte apoptosis in transgenic mice. Biochem Biophys Res Commun 477:541\u2013547. https:\/\/doi.org\/10.1016\/J.BBRC.2016.06.051","journal-title":"Biochem Biophys Res Commun"},{"key":"10562_CR249","doi-asserted-by":"publisher","DOI":"10.21037\/ATM-20-6073","volume":"9","author":"M Zheng","year":"2021","unstructured":"Zheng M, Wang M (2021) A narrative review of the roles of the miR-15\/107 family in heart disease: lessons and prospects for heart disease. Ann Transl Med 9:66. https:\/\/doi.org\/10.21037\/ATM-20-6073","journal-title":"Ann Transl Med"},{"key":"10562_CR250","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1042\/CS20160916","volume":"131","author":"S Rawal","year":"2017","unstructured":"Rawal S, Munasinghe PE, Nagesh PT et al (2017) Down-regulation of miR-15a\/b accelerates fibrotic remodelling in the type 2 diabetic human and mouse heart. Clin Sci 131:847\u2013863. https:\/\/doi.org\/10.1042\/CS20160916","journal-title":"Clin Sci"},{"key":"10562_CR251","doi-asserted-by":"publisher","unstructured":"Singh RM, Waqar T, Howarth FC, et al (2017) Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart. Heart Fail Rev 23:37\u201354. https:\/\/doi.org\/10.1007\/S10741-017-9663-Y","DOI":"10.1007\/S10741-017-9663-Y"},{"key":"10562_CR252","doi-asserted-by":"publisher","unstructured":"Copier CU, Le\u00f3n L, Fern\u00e1ndez M et al (2017) Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy. Sci Rep 7:1\u201311. https:\/\/doi.org\/10.1038\/s41598-017-13875-2","DOI":"10.1038\/s41598-017-13875-2"},{"key":"10562_CR253","first-page":"179","volume":"30","author":"T Melak","year":"2019","unstructured":"Melak T, Baynes HW (2019) Circulating microRNAs as possible biomarkers for coronary artery disease: a narrative review. EJIFCC 30:179","journal-title":"EJIFCC"},{"key":"10562_CR254","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1536\/IHJ.18-476","volume":"60","author":"ZD Ge","year":"2019","unstructured":"Ge ZD, Lian Q, Mao X, Xia Z (2019) Current status and challenges of NRF2 as a potential therapeutic target for diabetic cardiomyopathy. Int Heart J 60:512\u2013520. https:\/\/doi.org\/10.1536\/IHJ.18-476","journal-title":"Int Heart J"},{"key":"10562_CR255","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS222111939","volume":"22","author":"A Mata","year":"2021","unstructured":"Mata A, Cadenas S (2021) The antioxidant transcription factor Nrf2 in cardiac ischemia\u2013reperfusion injury. Int J Mol Sci 22:11939. https:\/\/doi.org\/10.3390\/IJMS222111939","journal-title":"Int J Mol Sci"},{"key":"10562_CR256","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5913374","volume":"2022","author":"Z Tang","year":"2022","unstructured":"Tang Z, Wang P, Dong C (2022) Oxidative stress signaling mediated pathogenesis of diabetic cardiomyopathy. Oxid Med Cell Longev 2022:5913374. https:\/\/doi.org\/10.1155\/2022\/5913374","journal-title":"Oxid Med Cell Longev"},{"key":"10562_CR257","doi-asserted-by":"publisher","first-page":"1451100","DOI":"10.3389\/FENDO.2024.1451100\/XML","volume":"15","author":"P Galis","year":"2024","unstructured":"Galis P, Bartosova L, Farkasova V et al (2024) Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy. Front Endocrinol (Lausanne) 15:1451100. https:\/\/doi.org\/10.3389\/FENDO.2024.1451100\/XML","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10562_CR258","doi-asserted-by":"publisher","first-page":"410976","DOI":"10.3389\/FENDO.2018.00642\/EPUB","volume":"9","author":"S Ducheix","year":"2018","unstructured":"Ducheix S, Magr\u00e9 J, Cariou B, Prieur X (2018) Chronic O-GlcNAcylation and diabetic cardiomyopathy: the bitterness of glucose. Front Endocrinol (Lausanne) 9:410976. https:\/\/doi.org\/10.3389\/FENDO.2018.00642\/EPUB","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10562_CR259","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBAMCR.2022.119365","volume":"1869","author":"H Hao","year":"2022","unstructured":"Hao H, Dai C, Han X, Li Y (2022) A novel therapeutic strategy for alleviating atrial remodeling by targeting exosomal miRNAs in atrial fibrillation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1869:119365. https:\/\/doi.org\/10.1016\/J.BBAMCR.2022.119365","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"4","key":"10562_CR260","doi-asserted-by":"publisher","DOI":"10.3390\/METABO13040479","volume":"13","author":"AB Reiss","year":"2023","unstructured":"Reiss AB, Ahmed S, Johnson M (2023) Exosomes in cardiovascular disease: from mechanism to therapeutic target. Metabolites 479. https:\/\/doi.org\/10.3390\/METABO13040479","journal-title":"Metabolites"},{"key":"10562_CR261","doi-asserted-by":"publisher","unstructured":"Fu X, Mishra R, Chen L et al (2023) Exosomes mediated fibrogenesis in dilated cardiomyopathy through a MicroRNA pathway. iScience 26:105963. https:\/\/doi.org\/10.1016\/J.ISCI.2023.105963\/ATTACHMENT\/E3245EAF-2C1A-4843-BC7F-6452159FDC29\/MMC1.PDF","DOI":"10.1016\/J.ISCI.2023.105963\/ATTACHMENT\/E3245EAF-2C1A-4843-BC7F-6452159FDC29\/MMC1.PDF"},{"key":"10562_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/J.LFS.2024.123063","volume":"357","author":"SF Ameer","year":"2024","unstructured":"Ameer SF, Elsaka M, Kahtoon S et al (2024) Exploring the role of exosomes in the pathogenesis and treatment of cardiomyopathies: a comprehensive literature review. Life Sci 357:123063. https:\/\/doi.org\/10.1016\/J.LFS.2024.123063","journal-title":"Life Sci"},{"key":"10562_CR263","doi-asserted-by":"publisher","first-page":"1327495","DOI":"10.3389\/FENDO.2023.1327495\/BIBTEX","volume":"14","author":"S Gao","year":"2023","unstructured":"Gao S, Dong Y, Yan C et al (2023) The role of exosomes and exosomal microRNA in diabetic cardiomyopathy. Front Endocrinol (Lausanne) 14:1327495. https:\/\/doi.org\/10.3389\/FENDO.2023.1327495\/BIBTEX","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10562_CR264","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/CVR\/CVV260","volume":"109","author":"NA Garcia","year":"2016","unstructured":"Garcia NA, Moncayo-Arlandi J, Sepulveda P, Diez-Juan A (2016) Cardiomyocyte exosomes regulate glycolytic flux in endothelium by direct transfer of GLUT transporters and glycolytic enzymes. Cardiovasc Res 109:397\u2013408. https:\/\/doi.org\/10.1093\/CVR\/CVV260","journal-title":"Cardiovasc Res"},{"key":"10562_CR265","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.2337\/DB15-1563","volume":"65","author":"X Wang","year":"2016","unstructured":"Wang X, Gu H, Huang W et al (2016) Hsp20-mediated activation of exosome biogenesis in cardiomyocytes improves cardiac function and angiogenesis in diabetic mice. Diabetes 65:3111\u20133128. https:\/\/doi.org\/10.2337\/DB15-1563","journal-title":"Diabetes"},{"key":"10562_CR266","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-59225-7","author":"V Casieri","year":"2020","unstructured":"Casieri V, Matteucci M, Pasanisi EM et al (2020) Ticagrelor enhances release of anti-hypoxic cardiac progenitor cell-derived exosomes through increasing cell proliferation in vitro. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-020-59225-7","journal-title":"Sci Rep"},{"key":"10562_CR267","doi-asserted-by":"publisher","DOI":"10.1186\/S13287-020-01824-2","author":"M Yu","year":"2020","unstructured":"Yu M, Liu W, Li J et al (2020) Exosomes derived from atorvastatin-pretreated MSC accelerate diabetic wound repair by enhancing angiogenesis via AKT\/eNOS pathway. Stem Cell Res Ther. https:\/\/doi.org\/10.1186\/S13287-020-01824-2","journal-title":"Stem Cell Res Ther"},{"key":"10562_CR268","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/S12015-025-10860-5","volume":"21","author":"X Gu","year":"2025","unstructured":"Gu X, Li T, Yin X et al (2025) Exosomes derived from metformin-pretreated BMSCs accelerate diabetic wound repair by promoting angiogenesis via the LINC-PINT\/miR-139-3p\/FOXC2 axis. Stem Cell Rev Rep 21:1096\u20131112. https:\/\/doi.org\/10.1007\/S12015-025-10860-5","journal-title":"Stem Cell Rev Rep"},{"key":"10562_CR269","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/S12967-023-04155-X","volume":"21","author":"G Papini","year":"2023","unstructured":"Papini G, Furini G, Matteucci M et al (2023) Cardiomyocyte-targeting exosomes from sulforaphane-treated fibroblasts affords cardioprotection in infarcted rats. J Transl Med 21:313. https:\/\/doi.org\/10.1186\/S12967-023-04155-X","journal-title":"J Transl Med"},{"key":"10562_CR270","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1007\/S00394-021-02594-0","volume":"60","author":"DC Mantilla-Escalante","year":"2021","unstructured":"Mantilla-Escalante DC, de L\u00f3pez las Hazas MC, Crespo MC et al (2021) Mediterranean diet enriched in extra-virgin olive oil or nuts modulates circulating exosomal non-coding RNAs. Eur J Nutr 60:4279\u20134293. https:\/\/doi.org\/10.1007\/S00394-021-02594-0","journal-title":"Eur J Nutr"},{"key":"10562_CR271","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2014.00005","volume":"5","author":"A Mattiazzi","year":"2014","unstructured":"Mattiazzi A, Kranias EG (2014) The role of CaMKII regulation of phospholamban activity in heart disease. Front Pharmacol 5:5. https:\/\/doi.org\/10.3389\/FPHAR.2014.00005","journal-title":"Front Pharmacol"},{"key":"10562_CR272","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007004","author":"T Witsch","year":"2018","unstructured":"Witsch T, Martinod K, Sorvillo N (2018) Recombinant human ADAMTS13 treatment improves myocardial remodeling and functionality after pressure overload injury in mice. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.117.007004","journal-title":"J Am Heart Assoc"},{"key":"10562_CR273","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/CIRCRESAHA.120.318402","volume":"129","author":"B Hegyi","year":"2021","unstructured":"Hegyi B, Fasoli A, Ko CY et al (2021) CaMKII serine 280 o-GlcNAcylation links diabetic hyperglycemia to proarrhythmia. Circ Res 129:98\u2013113. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.318402","journal-title":"Circ Res"},{"key":"10562_CR274","doi-asserted-by":"publisher","DOI":"10.1111\/JTH.12221","volume":"11","author":"XL Zheng","year":"2013","unstructured":"Zheng XL (2013) Structure-function and regulation of ADAMTS13 protease. J Thromb Haemost 11:11. https:\/\/doi.org\/10.1111\/JTH.12221","journal-title":"J Thromb Haemost"},{"key":"10562_CR275","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1161\/ATVBAHA.117.309539\/SUPPL_FILE\/ATVB_ATVB-2017-309539D_SUPP2.PDF","volume":"37","author":"N Dhanesha","year":"2017","unstructured":"Dhanesha N, Doddapattar P, Chorawala MR et al (2017) ADAMTS13 retards progression of diabetic nephropathy by inhibiting intrarenal thrombosis in mice. Arterioscler Thromb Vasc Biol 37:1332\u20131338. https:\/\/doi.org\/10.1161\/ATVBAHA.117.309539\/SUPPL_FILE\/ATVB_ATVB-2017-309539D_SUPP2.PDF","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10562_CR276","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/ANNUREV-MED-061813-013241","volume":"66","author":"XL Zheng","year":"2015","unstructured":"Zheng XL (2015) ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 66:211\u2013225. https:\/\/doi.org\/10.1146\/ANNUREV-MED-061813-013241","journal-title":"Annu Rev Med"},{"key":"10562_CR277","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2337\/DB17-1508","volume":"67","author":"P Cassis","year":"2018","unstructured":"Cassis P, Cerullo D, Zanchi C et al (2018) ADAMTS13 deficiency shortens the life span of mice with experimental diabetes. Diabetes 67:2069\u20132083. https:\/\/doi.org\/10.2337\/DB17-1508","journal-title":"Diabetes"},{"key":"10562_CR278","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.yjmcc.2009.10.016","volume":"48","author":"M Grimm","year":"2010","unstructured":"Grimm M, Brown JH (2010) \u03b2-adrenergic receptor signaling in the heart: role of CaMKII. J Mol Cell Cardiol 48:322\u2013330. https:\/\/doi.org\/10.1016\/j.yjmcc.2009.10.016","journal-title":"J Mol Cell Cardiol"},{"key":"10562_CR279","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/NATURE12537","volume":"502","author":"JR Erickson","year":"2013","unstructured":"Erickson JR, Pereira L, Wang L et al (2013) Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 502:372\u2013376. https:\/\/doi.org\/10.1038\/NATURE12537","journal-title":"Nature"},{"key":"10562_CR280","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.yjmcc.2011.01.012","volume":"51","author":"ME Anderson","year":"2011","unstructured":"Anderson ME, Brown JH, Bers DM (2011) CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 51:468\u2013473. https:\/\/doi.org\/10.1016\/j.yjmcc.2011.01.012","journal-title":"J Mol Cell Cardiol"},{"key":"10562_CR281","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1182\/BLOOD-2006-07-038166","volume":"109","author":"CKNK Chion","year":"2007","unstructured":"Chion CKNK, Doggen CJM, Crawley JTB et al (2007) ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109:1998\u20132000. https:\/\/doi.org\/10.1182\/BLOOD-2006-07-038166","journal-title":"Blood"},{"key":"10562_CR282","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2023.106918","volume":"196","author":"SXH Mthembu","year":"2023","unstructured":"Mthembu SXH, Mazibuko-Mbeje SE, Moetlediwa MT et al (2023) Sulforaphane: a nutraceutical against diabetes-related complications. Pharmacol Res 196:106918. https:\/\/doi.org\/10.1016\/J.PHRS.2023.106918","journal-title":"Pharmacol Res"},{"key":"10562_CR283","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7857186","volume":"2016","author":"CA Houghton","year":"2016","unstructured":"Houghton CA, Fassett RG, Coombes JS (2016) Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician\u2019s expectation be matched by the reality? Oxid Med Cell Longev 2016:7857186. https:\/\/doi.org\/10.1155\/2016\/7857186","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"10562_CR284","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/DOM.15369","volume":"26","author":"L Zhou","year":"2024","unstructured":"Zhou L, Su W, Wang Y et al (2024) FOXO1 reduces STAT3 activation and causes impaired mitochondrial quality control in diabetic cardiomyopathy. Diabetes Obes Metab 26(2):732\u2013744. https:\/\/doi.org\/10.1111\/DOM.15369","journal-title":"Diabetes Obes Metab"},{"key":"10562_CR285","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/BIOMEDICINES10061316\/S1","volume":"10","author":"YL Molina","year":"2022","unstructured":"Molina YL, Garc\u00eda-seisdedos D, Babiy B et al (2022) Rottlerin stimulates exosome\/microvesicle release via the increase of ceramide levels mediated by Ampk in an in vitro model of intracellular lipid accumulation. Biomedicines 10:1316. https:\/\/doi.org\/10.3390\/BIOMEDICINES10061316\/S1","journal-title":"Biomedicines"},{"key":"10562_CR286","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.3390\/IJMS22115973","volume":"22","author":"P Grubi\u0107 Rotkvi\u0107","year":"2021","unstructured":"Grubi\u0107 Rotkvi\u0107 P, Planini\u0107 Z, Liberati Pr\u0161o AM et al (2021) The mystery of diabetic cardiomyopathy: from early concepts and underlying mechanisms to novel therapeutic possibilities. Int J Mol Sci 22:5973. https:\/\/doi.org\/10.3390\/IJMS22115973","journal-title":"Int J Mol Sci"},{"key":"10562_CR287","doi-asserted-by":"publisher","DOI":"10.12997\/JLA.2022.11.2.161","volume":"11","author":"A Tarkhnishvili","year":"2022","unstructured":"Tarkhnishvili A, Koentges C, Pfeil K et al (2022) Effects of short term adiponectin receptor agonism on cardiac function and energetics in diabetic db\/db mice. J Lipid Atheroscler 11:161. https:\/\/doi.org\/10.12997\/JLA.2022.11.2.161","journal-title":"J Lipid Atheroscler"},{"key":"10562_CR288","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21608\/BLJ.2022.280658","volume":"18","author":"A-SM Abas","year":"2022","unstructured":"Abas A-SM, Mohamed FZ, Bayomi AR, Gad EM (2022) Biochemical studies on benzimidazole compounds as anti-diabetic agents. Biochemistry Letters 18:33\u201355. https:\/\/doi.org\/10.21608\/BLJ.2022.280658","journal-title":"Biochemistry Letters"},{"key":"10562_CR289","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7536803","volume":"2019","author":"QQ Wu","year":"2019","unstructured":"Wu QQ, Deng W, Xiao Y et al (2019) The 5-lipoxygenase inhibitor zileuton protects pressure overload-induced cardiac remodeling via activating PPAR\u03b1. Oxid Med Cell Longev 2019:7536803. https:\/\/doi.org\/10.1155\/2019\/7536803","journal-title":"Oxid Med Cell Longev"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10562-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10562-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10562-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:04:27Z","timestamp":1763150667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10562-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":289,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10562"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10562-7","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare that there are no conflicts of interest related to this research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}